

Weekly

December 12, 2008 / Vol. 57 / No. 49

Asbestosis-Related Years of Potential Life Lost Before Age 65 Years – United States, 1968–2005

Exposure to asbestos fibers can cause asbestosis and other diseases (1) after a latency of 10-40 years from initial exposure to onset of illness. Asbestos still is used in the United States (approximately 2,200 metric tons in 2006) in certain products manufactured domestically (2). In addition, an undocumented amount of asbestos continues to be imported in products manufactured elsewhere, and a substantial amount of asbestos remains in existing buildings and manufactured products. An estimated 1.3 million construction and general industry workers in the United States potentially are exposed to asbestos each year, mainly from manipulation of asbestos during renovation or demolition activities (3). Also, although asbestos ore is no longer mined in the United States (4), some U.S. mine workers might remain at risk for exposure to asbestos contained in other ores. To characterize trends in premature mortality attributed to asbestosis in the United States, CDC analyzed annual underlying cause-of-death data for 1968-2005, the most recent years for which data were available.* This report describes the results of that analysis, which indicated that annual years of potential life lost before age 65 years (YPLL) attributed to asbestosis increased 64%, from an average of 146.0 YPLL per year during 1968-1972 to 239.6 per year during 2001-2005 (regression trend for the 5-year moving average, p<0.001), for an overall total of 7,267 YPLL (mean per decedent: 6.2) over the entire period. These results demonstrate that asbestosis-attributable YPLL continue to occur and that efforts to prevent, track, and eliminate asbestosis need to be maintained.

For this analysis, decedents for whom the *International Classification of Diseases* (ICD) code for asbestosis was listed as the underlying cause of death were identified from 1968–2005 mortality data.[†] Given the occupational etiology and long latency of asbestosis, analysis was restricted to deaths of persons aged \geq 25 years. Standard industry and occupation information that met CDC quality criteria was available for decedents in 26 states during the 1985–1999 period.[§] After 1999, funds for coding industry and occupation were not available, and coding at the state level ceased. The number of states reporting data in any particular year varied from 16 to 22, and the number

INSIDE

- 1325 Potential Effects of Electronic Laboratory Reporting on Improving Timeliness of Infectious Disease Notification – Florida, 2002–2006
- 1329 Update: Influenza Activity United States, September 28-November 29, 2008
- 1332 Notices to Readers
- 1333 QuickStats

^{*} Since 1968, CDC's National Center for Health Statistics (NCHS) has compiled multiple cause-of-death data annually from death certificates in the United States. CDC's National Institute for Occupational Safety and Health (NIOSH) extracts information on deaths from occupationally related respiratory diseases and conditions from the NCHS data and stores the information in the National Occupational Respiratory Mortality System (NORMS), available at http:// webappa.cdc.gov/ords/norms.html.

[†] ICDA-8 code 515.2 (asbestosis) for years 1968–1978, ICD-9 code 501 (asbestosis) for years 1979–1998, and ICD-10 code J61 (pneumoconiosis due to asbestos and other mineral fibers) for years 1999–2005. For years 1999–2005, decedents with ICD-10 underlying cause coded as J65 (pneumoconiosis associated with tuberculosis) or J92.0 (pleural plaque with presence of asbestos) also were included in the underlying cause-of-death tabulation for asbestosis if code J61 also was listed on the death certificate.

[§] Alaska, Colorado, Georgia, Hawaii, Idaho, Indiana, Kansas, Kentucky, Maine, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, North Carolina, Ohio, Oklahoma, Rhode Island, South Carolina, Tennessee, Utah, Vermont, Washington, West Virginia, and Wisconsin.

The *MMWR* series of publications is published by the Coordinating Center for Health Information and Service, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

Suggested Citation: Centers for Disease Control and Prevention. [Article title]. MMWR 2008;57:[inclusive page numbers].

Centers for Disease Control and Prevention

Julie L. Gerberding, MD, MPH Director Tanja Popovic, MD, PhD Chief Science Officer James W. Stephens, PhD Associate Director for Science Steven L. Solomon, MD Director, Coordinating Center for Health Information and Service Jay M. Bernhardt, PhD, MPH Director, National Center for Health Marketing Katherine L. Daniel, PhD Deputy Director, National Center for Health Marketing

Editorial and Production Staff

Frederic E. Shaw, MD, JD Editor, MMWR Series Susan F. Davis, MD (Acting) Assistant Editor, MMWR Series Robert A. Gunn, MD, MPH Associate Editor, MMWR Series Teresa F. Rutledge Managing Editor, MMWR Series Douglas W. Weatherwax Lead Technical Writer-Editor Donald G. Meadows, MA Jude C. Rutledge Writers-Editors Martha F. Boyd Lead Visual Information Specialist Malbea A. LaPete Stephen R. Spriggs Visual Information Specialists Kim L. Bright, MBA Quang M. Doan, MBA Phyllis H. King Information Technology Specialists

Editorial Board

William L. Roper, MD, MPH, Chapel Hill, NC, Chairman Virginia A. Caine, MD, Indianapolis, IN David W. Fleming, MD, Seattle, WA William E. Halperin, MD, DrPH, MPH, Newark, NJ Margaret A. Hamburg, MD, Washington, DC King K. Holmes, MD, PhD, Seattle, WA Deborah Holtzman, PhD, Atlanta, GA John K. Iglehart, Bethesda, MD Dennis G. Maki, MD, Madison, WI Sue Mallonee, MPH, Oklahoma City, OK Patricia Quinlisk, MD, MPH, Des Moines, IA Patrick L. Remington, MD, MPH, Madison, WI Barbara K. Rimer, DrPH, Chapel Hill, NC John V. Rullan, MD, MPH, San Juan, PR William Schaffner, MD, Nashville, TN Anne Schuchat, MD, Atlanta, GA Dixie E. Snider, MD, MPH, Atlanta, GA John W. Ward, MD, Atlanta, GA

of years of data available for any one state varied from 2 to 15. Industry and occupation were classified according to two U.S. Census Bureau coding systems.⁹ YPLL and mean YPLL were calculated using 5-year age groups and standard methodology (5). A simple linear regression model was used for time-trend analysis of YPLL (using 5-year moving averages).

During 1968–2005, asbestosis was identified as the underlying cause of death for 9,024 decedents. Of these, 1,169 (13.0%) were aged 25–64 years, including one (0.1%) decedent aged 25–34 years; 17 (1.5%) aged 35–44 years; 165 (14.1%) aged 45–54 years; and 986 (84.3%) aged 55–64 years, accounting for 7,267 YPLL (mean per decedent: 6.2). The majority of asbestosis decedents aged 25–64 years were male (1,125 [96.2%]) and white (1,064 [91.0%]), accounting for 7,038 (96.8%) and 6,470 (89.0%) YPLL, respectively (Table 1).

YPLL attributed to asbestosis deaths increased 64%, from an average of 146.0 per year during 1968–1972 to 239.6 per year during 2001–2005 (regression trend, p<0.001). YPLL varied annually, from a low of 69 (mean per decedent: 8.6) in 1973 to a high of 306 (mean per decedent: 5.9) in 1990 (Figure). The rate varied annually, from a low of 0.73 per million in 1973 to a high of 2.78 per million in 1970. During 1968–2005, asbestosis deaths in Texas (85; 577 YPLL), Pennsylvania (99; 544 YPLL), New Jersey (90; 527 YPLL), and California (76; 468 YPLL) accounted for 29.9% of all decedents aged 25–64 years with asbestosis as the underlying cause of death and 29.1% of the total YPLL attributed to asbestosis (Table 1).

Industry and occupation information was available for 153 (28.8%) of the 531 decedents aged 25–64 years with asbestosis as the underlying cause of death during 1985–1999 (Table 2). Of 54 industries reported, the greatest YPLL were in construction (244 YPLL; mean per decedent: 5.7); ship and boat building and repairing (41; mean per decedent: 5.9); and military (41; mean per decedent: 5.9). Of 59 occupations reported, the greatest YPLL were for insulation workers (112; mean per decedent: 5.9); managers and administrators, not elsewhere classified (43; mean per decedent: 7.2); and plumbers, pipefitters, and steamfitters (42; mean per decedent: 4.7).

Reported by: JM Mazurek, MD, JM Wood, MS, Div of Respiratory Disease Studies, National Institute for Occupational Safety and Health, CDC.

Editorial Note: YPLL are a measure of premature mortality that emphasizes deaths occurring among younger persons during their most productive years (5,6). Persons dying before

⁹ Industry and occupation information from death certificates was coded on the NCHS multiple cause-of-death data files according to the 1980 U.S. Bureau of Census Index of Industries and Occupations classification system from1985 to 1992, and according to the 1990 U.S. Bureau of Census classification system from 1993 to 1999. For the industries and occupations listed in this report, the 1980 and 1990 classification system codes and titles were the same.

	De	eaths	Y	PLL	Mean		Dea	aths	YP	LL	Mean	
Characteristic	No.	(%)	No.	(%)	YPLL per decedent	Characteristic	No.	(%)	No.	(%)	YPLL per decedent	
Total	1,169	(100.0)	7,267	(100.0)	6.2	State of residence						
Sex						Michigan	29	(2.5)	182	(2.5)	6.3	
Male	1,125	(96.2)	7,038	(96.8)	6.3	Minnesota	16	(1.4)	123	(1.7)	7.7	
Female	44	(3.8)	229	(3.2)	5.2	Mississippi	26	(2.2)	143	(2.0)	5.5	
Race						Missouri	21	(1.8)	143	(2.0)	6.8	
White	1,064	(91.0)	6,470	(89.0)	6.1	Montana	6	(0.5)	38	(0.5)	6.3	
Black	98	(8.4)	766	(10.5)	7.8	Nebraska	1	(0.1)	8	(0.1)	8.0	
Other	7	(0.6)	31	(0.4)	4.4	Nevada	7	(0.6)	56	(0.8)	8.0	
State of residence		(0.0)		(011)		New Hampshire	6	(0.5)	33	(0.5)	5.5	
Alabama	30	(2.6)	180	(2.5)	6.0	New Jersey	90	(7.7)	527	(7.3)	5.9	
Alaska	30	(2.0)	3	(2.5)	3.0	New Mexico	4	(0.3)	22	(0.3)	5.5	
Arizona	13	(0.1)	84	(0.0)	6.5	New York	55	(4.7)	365	(5.0)	6.6	
Arkansas	13	(1.1)	04 71	(1.2)	5.9	North Carolina	30	(2.6)	235	(3.2)	7.8	
California	76	(1.0)	468	(1.0)	6.2	North Dakota	1	(0.1)	3	(0.0)	3.0	
Colorado	70	(0.3)	400	(0.4)	5.5	Ohio	50	(4.3)	340	(4.7)	6.8	
Connecticut	16	(0.3)	78	(0.3)	4.9	Oklahoma	5	(0.4)	25	(0.3)	5.0	
Delaware	11	· · ·	78	· · ·	4.9 7.1	Oregon	19	(1.6)	107	(1.5)	5.6	
Delaware District of Columbia	2	(0.9) (0.2)	78 21	(1.1) (0.3)	10.5	Pennsylvania	99	(8.5)	544	(7.5)	5.5	
Florida	2 60	(0.2)	340	(0.3)	5.7	Rhode Island	8	(0.7)	79	(1.1)	9.9	
	27	· · ·	173	(4.7)	6.4	South Carolina	31	(2.7)	140	(1.9)	4.5	
Georgia		(2.3)		· · ·	8.4 3.0	South Dakota	0	(0.0)	0	(0.0)	0.0	
Hawaii Idaho	5 6	(0.4)	15 38	(0.2)	6.3	Tennessee	20	(1.7)	135	(1.9)	6.8	
	31	(0.5)	38 187	(0.5)	6.0	Texas	85	(7.3)	577	(7.9)	6.8	
Illinois Indiana		(2.7)	25	(2.6)	5.0	Utah	2	(0.2)	16	(0.2)	8.0	
	5	(0.4)	∠5 53	(0.3)		Vermont	1	(0.1)	3	(0.0)	3.0	
lowa	6	(0.5)	53 38	(0.7)	8.8	Virginia	49	(4.2)	292	(4.0)	6.0	
Kansas	6 11	(0.5)	38 63	(0.5)	6.3	Washington	41	(3.5)	293	(4.0)	7.1	
Kentucky		(0.9)		(0.9)	5.7	West Virginia	17	(1.5)	86	(1.2)	5.1	
Louisiana	33	(2.8)	261	(3.6)	7.9	Wisconsin	15	(1.3)	82	(1.1)	5.5	
Maine	6	(0.5)	33	(0.5)	5.5	Wyoming	1	(0.1)	8	(0.1)	8.0	
Maryland	31	(2.7)	188	(2.6)	6.1			. ,		. ,		
Massachusetts	42	(3.6)	243	(3.3)	5.8							

TABLE 1. Years of potential life lost before age 65 years (YPLL) for decedents aged 25–64 years with asbestosis as the underlying cause of death,* by sex, race, and state of residence — United States, 1968–2005


* Decedents for whom the International Classification of Diseases (ICD) code for asbestosis was listed as the underlying cause of death were identified from 1968–2005 mortality data. ICDA-8 code 515.2 (asbestosis) for years 1968–1978, ICD-9 code 501 (asbestosis) for years 1979–1998, and ICD-10 code J61 (pneumoconiosis due to asbestos and other mineral fibers) for years 1999–2005. For years 1999–2005, decedents with ICD-10 underlying cause coded as J65 (pneumoconiosis associated with tuberculosis) or J92.0 (pleural plaque with presence of asbestos) also were included in the underlying cause of death tabulation for asbestosis if code J61 also was listed on the death certificate.

age 65 years are considered as having years of potential work tenure lost, on the assumption that these are a worker's most productive years. During 1968-2005, asbestosis was identified as the underlying cause of death for 1,169 decedents aged 25–64 years, accounting for 7,267 YPLL. Overall, a mean of 6.2 YPLL per decedent was attributed to asbestosis during 1968–2005, indicating that, on average, decedents aged 25–64 years with asbestosis listed as the underlying cause of death died at age 58 years. Despite the decline in asbestos use and reduced exposures, the findings described in this report indicate that asbestosis-attributable YPLL continue to occur. Because asbestosis mortality typically manifests several decades after initial exposure to asbestos, much of the continuing YPLL likely is attributed to exposures experienced decades ago. During 1970-2004, the annual number of asbestosis-related deaths (based on the analysis of asbestosis deaths coded on the entity

axis in multiple cause-of-death files^{**}) in the United States increased nearly 17-fold, from 89 (age-adjusted death rate: 0.6 per million persons aged >15 years) in 1970 to 1,493 (6.9) in 2000, and then declined slightly to 1,470 (6.3) in 2004, for an overall total of 25,413 asbestosis deaths over the entire period (7). This slight decline in the age-adjusted death rate was attributed to several factors, including reduced use of asbestos and improved control of asbestos exposure (8,9). Beginning several decades ago, increased awareness of the health consequences of asbestos exposure stimulated voluntary and regulatory actions by the Environmental Protection Agency and the Occupational Safety and Health Administration (8,9).

^{**} Entity axis includes information on all of the diseases, injuries, or medical complications, as well as the location (part, line, and sequence) of the information recorded on each death certificate. "Detail Record Layout" available at http://www.cdc.gov/nchs/about/major/dvs/mcd/1998mcd.htm.

FIGURE. Number of deaths among persons aged \geq 25 years with asbestosis as the underlying cause of death,* years of potential life lost before age 65 years (YPLL) for decedents aged 25–64 years, and asbestos use — United States, 1900–2006



* Decedents for whom the International Classification of Diseases (ICD) code for asbestosis was listed as the underlying cause of death were identified from 1968–2005 mortality data. ICDA-8 code 515.2 (asbestosis) for years 1968–1978, ICD-9 code 501 (asbestosis) for years 1979–1998, and ICD-10 code J61 (pneumoconiosis due to asbestos and other mineral fibers) for years 1999–2005. For years 1999–2005, decedents with ICD-10 underlying cause coded as J65 (pneumoconiosis associated with tuberculosis) or J92.0 (pleural plaque with presence of asbestos) also were included in the underlying cause of death tabulation for asbestosis if code J61 also was listed on the death certificate.

Available data (for 153 decedents) indicated that the greatest industry-specific YPLL values were associated with work in construction and ship and boat building and repairing, which is consistent with documented past industry-specific asbestos exposures (1). Likewise, two of the three occupations with the greatest YPLL values, insulation workers and plumbers, pipefitters, and steamfitters, are well known to have been associated with asbestos exposures.

The findings in this report are subject to at least six limitations. First, this report used a death certificate–based definition of asbestosis as the underlying cause of death. Because some deaths from asbestosis might have been attributed to other diseases (e.g., idiopathic pulmonary fibrosis) instead of to asbestosis, the findings in this report likely underestimate deaths and YPLL attributable to asbestosis. Second, complete work histories are not listed on death certificates, and the relevance of the reported usual industry and occupation to actual hazardous exposures could not be verified. Although no studies have examined the accuracy of usual industry and occupation information on death certificates specifically for asbestosis decedents, research suggests a generally good agreement of this information compared with that from other sources (10). Third, coded information on usual industry and occupation were available for decedents in only 26 states, accounting for 28.8% of all U.S. asbestosis decedents during 1985-1999. Thus, these data might not be nationally representative for 1985–1999. Fourth, the state issuing a death certificate is not always the state in which the decedent's asbestos exposure occurred. Fifth, ICD cause-of-death codes used in this analysis changed twice during 1968-2005. However, these revisions likely did not introduce bias or affect the temporal trend in asbestosis deaths (7). Finally, YPLL, as calculated, do not account for the full burden of asbestosis. During the period for which CDC analyzed U.S. death data, approximately 87% of the deaths with asbestosis listed as the underlying cause of death occurred in persons aged ≥ 65 years. Moreover, although YPLL do reflect premature mortality during the most productive years of life, YPLL do not account for all reduced quality of life or work years lost attributed to disability from asbestosis. Persons with asbestosis can live for many years with severely limited lung function and few treatment options, leading to inability to work.

The continuing occurrence of cases of asbestos in younger persons (asbestosis-attributable YPLL) underscores the need for persistent asbestosis prevention and elimination efforts. Effective primary prevention is critical because asbestos-related diseases can develop or progress even after occupational exposure ends. Guidance for persons concerned about exposure to asbestos and for health-care providers who work with patients potentially exposed to asbestos is available at http://www.cdc. gov/health/asbestos.htm. CDC continues to conduct surveillance for asbestosis and other asbestos-related deaths to follow trends and identify problems.

Acknowledgments

This report is based, in part, on contributions by RM Castellan, MD, and PJ Middendorf, PhD, National Institute for Occupational Safety and Health, CDC.

References

- Rom WN. Asbestos-related lung disease. In: Fishman AP, Elias JA, Fishman JA, Grippi MA, Senior RM, Pack AI, eds. Fishman's pulmonary diseases and disorders. 4th ed. New York, NY: McGraw-Hill Medical; 2008:943–58.
- Kelly TD, Matos GR. Historical statistics for mineral and material commodities in the United States: US Geological Survey data series 140. Reston, VA: US Geological Survey; 2007. Available at http://minerals.usgs.gov/ds/2005/140.
- US Department of Labor. Better protection against asbestos in the workplace. Fact sheet no. OSHA 92-06. Available at http://www. pp.okstate.edu/ehs/training/oshasbes.htm.
- Van Gosen BS. Reported historic asbestos mines, historic asbestos prospects, and natural asbestos occurrences in the eastern United States. US Geological Survey open-file report 2005–1189. Reston, VA: US Geological Survey; 2006. Available at http://pubs.usgs.gov/ of/2005/1189.

All other occupations

			YPLL (N = 869))
	Deaths			Mean YPLL per
Industry and occupation [§]	(N = 153)	No.	(%)	decedent
Industry (Census Industry Code)				
Construction (060)	43	244	(28.1)	5.7
Ship and boat building and repairing (360)	7	41	(4.7)	5.9
Military (942)	7	41	(4.7)	5.9
Automotive repair and related services (751)	5	35	(4.0)	7.0
Motor vehicles and motor vehicle equipment (351)	2	31	(3.6)	15.5
Industrial and miscellaneous chemicals (192)	4	22	(2.5)	5.5
National security and international affairs (932)	3	19	(2.2)	6.3
Miscellaneous nonmetallic mineral and stone products (262)	3	19	(2.2)	6.3
Not specified metal industries (301)	1	18	(2.1)	18.0
Agricultural production, livestock (011)	1	18	(2.1)	18.0
Industry not reported	13	84	(9.7)	6.5
All other industries	64	297	(34.2)	4.6
Occupation (Census Occupation Code)				
Insulation workers (593)	19	112	(12.9)	5.9
Managers and administrators, not elsewhere classified (019)	6	43	(4.9)	7.2
Plumbers, pipefitters, and steamfitters (585)	9	42	(4.8)	4.7
Machinists (637)	5	40	(4.6)	8.0
Machine operators, not specified (779)	6	38	(4.4)	6.3
Electricians (575)	8	34	(3.9)	4.3
Automobile mechanics (505)	4	32	(3.7)	8.0
Military occupations (905)	5	30	(3.5)	6.0
Supervisors and proprietors, sales occupations (243)	3	29	(3.3)	9.7
Construction laborers (869)	5	25	(2.9)	5.0
Occupation not reported	10	50	(5.8)	5.0

TABLE 2. Top 10 industries and occupations with greatest years of potential life lost before age 65 years (YPLL) for decedents aged 25–64 years with asbestosis as the underlying cause of death* — selected U.S. states[†] and years, 1985–1999

* Decedents for whom the International Classification of Diseases (ICD) code for asbestosis was listed as the underlying cause of death were identified from mortality data using ICD-9 code 501 (asbestosis) for years 1979–1998, and ICD-10 code J61 (pneumoconiosis due to asbestos and other mineral fibers) for 1999. For 1999, decedents with ICD-10 underlying cause coded as J65 (pneumoconiosis associated with tuberculosis) or J92.0 (pleural plaque with presence of asbestos) also were included in the underlying cause of death tabulation for asbestosis if code J61 also was listed on the death certificate. [†] Alaska, Colorado, Georgia, Hawaii, Idaho, Indiana, Kansas, Kentucky, Maine, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico,

73

394

North Carolina, Ohio, Oklahoma, Rhode Island, South Carolina, Tennessee, Utah, Vermont, Washington, West Virginia, and Wisconsin.

[§] Industry and occupation information from death certificates was coded on the NCHS multiple cause-of-death data files according to the 1980 U.S. Bureau of Census Index of Industries and Occupations classification system from 1985 to 1992, and according to the 1990 U.S. Bureau of Census classification system from 1993 to 1999. For the industries and occupations listed, the 1980 and 1990 classification system codes and titles were the same.

- Wise RP, Livengood JR, Berkelman RL, Goodman RA. Methodological alternatives for measuring premature mortality. Am J Prev Med 1988;4:268–73.
- 6. CDC. Premature mortality in the United States: public health issues in the use of years of potential life lost. MMWR 1986;35(2 Suppl):1S–11S.
- Bang KM, Mazurek JM, Syamlal G, Wood JM. Asbestosis mortality surveillance in the United States, 1970–2004. Int J Occup Environ Health 2008;14:161–9.
- US Environmental Protection Agency. EPA asbestos materials bans: clarification. Available at http://www.epa.gov/oppt/asbestos/pubs/asbbans2.pdf.
- Martonik JF, Nash E, Grossman E. The history of OSHA's asbestos rule makings and some distinctive approaches that they introduced for regulating occupational exposure to toxic substances. AIHAJ 2001;62:208–17.
- 10. Steenland K, Beaumont J. The accuracy of occupation and industry data on death certificates. J Occup Med 1984;26:288–96.

Potential Effects of Electronic Laboratory Reporting on Improving Timeliness of Infectious Disease Notification – Florida, 2002–2006

(45.3)

5.4

Electronic laboratory reporting (ELR) potentially can improve the timeliness of notifiable disease case reporting and subsequent disease control activities (1,2), but the extent of this improvement and the resulting effects on the workload of state or local surveillance teams are unknown. To estimate those effects, investigators from the Florida Department of Health (FDOH) evaluated the timeliness of reporting for four notifiable diseases of varying incubation periods: salmonellosis, shigellosis, meningococcal disease, and hepatitis A. Investigators then calculated the potential improvement expected with ELR using the assumption that ELR can reduce to 1 day the time from completion of a diagnostic laboratory test to notification of the county health department (CHD) of the result. This report summarizes the results of that analysis, which showed that ELR would reduce the total time from symptom onset to CHD notification of a case by nearly half for salmonellosis (from 12 days to 7 days) and shigellosis (from 10 days to 6 days), but would produce no change for meningococcal disease (4 days) and minimal improvement for hepatitis A (from 13 days to 10 days). In Florida, the benefits of ELR for reporting timeliness likely will vary by disease.

The FDOH web-based reportable disease surveillance database (Merlin) was used to conduct this evaluation. The Florida Bureau of Epidemiology annually receives from CHDs approximately 30,000 reports of cases of notifiable infectious diseases. With full implementation of ELR, participating laboratories will transmit electronically all reportable laboratory results directly to Merlin, which can then be accessed by all CHD epidemiologists. To evaluate the potential of ELR to change the timeliness of disease reporting in Florida, FDOH investigators selected four key notifiable diseases, either because of high severity or significant public health concern: salmonellosis, shigellosis, meningococcal disease, and hepatitis A. Confirmed cases of the four diseases were analyzed for the study period, 2002–2006 (Box). Florida began implementation of ELR from commercial laboratories in 2006, but ELR was not in use for any of the four diseases included in this analysis during the study period.

The regular practice during the study period was for CHD epidemiologists to manually enter all data for the four diseases into Merlin, including dates of symptom onset (as reported by patients), laboratory reporting, and CHD notification. Symptom onset date was defined as the date of illness reported by patient. Laboratory reporting date was the date the laboratory report was mailed, faxed, or conveyed to the CHD by telephone. CHD notification date was the date the CHD recorded receipt of the laboratory report. However, all three date fields were not required for a final case report to be submitted through Merlin to FDOH. Three time intervals were calculated: symptom onset date to laboratory reporting date (interval A), laboratory reporting date to CHD notification date (interval B), and symptom onset date to CHD notification date (interval C). Next, the percentage of cases reported within one and two incubation periods for each disease was calculated. Incubation period was used as a proxy for period of transmissibility (3). The incubation period for each of the four diseases (1 day for salmonellosis, 3 days for shigellosis, 4 days for meningococcal disease, and 30 days for hepatitis A) was assumed to be the midpoint of the range most commonly reported in the literature (4, 5). Although the electronic transmission of laboratory reports is instantaneous, interval B BOX. Summary of notifiable disease case definitions used to assess potential timeliness effects of electronic laboratory reporting system — Florida, 2002–2006

Salmonellosis

- Laboratory criteria: isolation of *Salmonella* from a clinical specimen.
- Confirmed case: meets laboratory criteria for diagnosis.

Shigellosis

- Laboratory criteria: isolation of *Shigella* from a clinical specimen.
- Confirmed case: meets laboratory criteria for diagnosis.

Meningococcal disease

- Clinical description: meningitis or meningococcemia, purpura fulminans, and shock.
- Laboratory criteria: isolation of *Neisseria meningitidis* from a normally sterile site or skin scrapings of purpuric lesions.
- Confirmed case: a clinically compatible case that also meets laboratory criteria.

Hepatitis A

- Laboratory criteria: immunoglobulin M (IgM) antibody to hepatitis A virus (anti-HAV) positive.
- Clinical case definition: discrete onset of symptoms (might include fever, malaise, anorexia, nausea, and abdominal discomfort) and jaundice or elevated serum aminotransferase.
- Confirmed case: meets clinical case definition and is laboratory confirmed.

SOURCE: CDC. Nationally notifiable infectious diseases — United States, 2006. Available at http://www.cdc.gov/ncphi/disss/nndss/phs/infdis2006.htm.

was assumed to be 1 day when ELR was implemented because many laboratories batch their electronic reporting once per shift or once per day.

Among the 23,263 confirmed cases of salmonellosis reported during the 5-year period, 81% of reports included symptom onset date, 72% included laboratory reporting date, and 96% included CHD notification date. Time intervals A, B, and C could be calculated for 57%, 68%, and 78% of cases, respectively (Table 1). The median number of days for intervals A, B, and C were 6, 5, and 12, respectively (Table 2). If ELR were used for salmonellosis reporting, interval B would decrease from 5 days to 1 day, which would result in a decrease of interval C (symptom onset date to CHD notification date) from 12 to 7 days (Table 2, Figure). The percentage reported within two incubation periods would increase from 1% to 10%. Reporting

		Dates recorded		Intervals calculated						
Disease	Symptom onset* (%)	Laboratory reported [†] (%)	Reported to CHD [§] (%)	Symptom onset to laboratory report (A) (%)	Laboratory report to CHD notified (B) (%)	Symptom onset to CHD notified (C) (%)				
Salmonellosis (N = 23,263)	81	72	96	57	68	78				
Shigellosis (N = 8,014)	85	68	96	56	64	82				
Meningococcal disease (N = 450)	94	75	98	70	62	92				
Hepatitis A (N = $2,104$)	96	66	99	63	59	94				

TABLE 1. Percentage of laboratory records for which date was recorded in communicable disease reporting system (Merlin) and time intervals were calculated for four diseases — Florida, 2002–2006

* Date patient said symptoms began.

[†] Date reporting laboratory sent results to county health department.

§ County health department.

TABLE 2. Timeliness of reporting laboratory results for four diseases to county health department (CHD) for existing and projected
electronic laboratory reporting (ELR) systems — Florida, 2002–2006

							Existing	j system	Projected E	ELR system
	E	xisting syste	em	Proje	ected ELR sy	stem	Inter	val C	Inter	val C
Disease (Incubation period)	Interval A*	Interval B [†]	Interval C§	Interval A	Interval B [¶]	Interval C	% within 1 IP**	% within 2 IP**	% within 1 IP**	% within 2 IP**
Salmonellosis (1 day)	6	5	12	6	1	7	<1	1	4	10
Shigellosis (3 days)	5	4	10	5	1	6	5	28	22	60
Meningococcal disease										
(4 days)	3	1	4	3	1	4	61	84	84	94
Hepatitis A (30 days)	9	3	13	9	1	10	83	92	92	98

* Interval A = symptom onset date to laboratory report date.

[†] Interval B = laboratory report date to CHD notification date.

[§] Interval C = symptom onset date to CHD notification date.

¹ Although electronic transmission of laboratory reports is instantaneous, interval B was assumed to be 1 day when ELR is fully implemented because many laboratories batch their electronic reporting once per shift or once per day.

** Incubation period.

within two incubation periods would improve from 28% to 60% for shigellosis, from 84% to 94% for meningococcal disease, and from 92% to 98% for hepatitis A (Table 2).

Reported by: A Kite-Powell, MS, JJ Hamilton, MPH, RS Hopkins, MD, Florida Dept of Health. JM DePasquale, MD, EIS Officer, CDC.

Editorial Note: Investments in ELR systems for notifiable diseases generally are justified by expected improvements in timeliness and sensitivity of reporting. This analysis determined that, in Florida, improvements in timeliness in reporting would be highly disease specific. The greatest improvements in timeliness of reporting (i.e., the absolute number of days for CHDs to be notified of illness) would be expected for salmonellosis and shigellosis. In Florida, these two diseases often are reported by postal mail. With implementation of ELR, the reporting time from symptom onset to CHD notification would be nearly halved. These two diseases also would experience the greatest increase in timeliness of reporting within two incubation periods, in part because they have the shortest incubation periods of the four diseases tested in this analysis (1 and 3 days, respectively). When laboratory reports for a condition with a short incubation period are mailed from laboratory to CHD, only a small fraction of cases are reported to CHDs within two incubation periods. Results for meningococcal disease and hepatitis A, which have longer incubation periods, often are reported from laboratories by faster methods (fax or telephone). Because clinicians, laboratorians, and health departments already place great importance on timely reporting of meningococcal disease, more cases are reported within two incubation periods and the potential improvement with use of ELR is less. Under the assumptions of this analysis, the median number of days to report laboratory results to a CHD for meningococcal disease (1 day) would not change.

In addition to timeliness, the completeness of reporting dates will improve for all conditions reported with ELR, approaching 100% for the laboratory reporting and CHD notification dates, which will be required fields automatically populated by ELR software. This information will permit time intervals to be more completely calculated. The date of symptom onset and any time interval using this date are, however, dependent on patient recall and not on programming of surveillance system software.




FIGURE. Distribution of reporting time from symptom onset date to date the county health department is notified of the case (interval C) — Florida, 2002–2006

The findings in this report are subject to at least three limitations. First, depending on the disease and category of date, from 1% to 33% of key dates were missing from the Merlin database (Table 1). Results might have differed if all such dates had been available for all cases. Second, interpretation and application of date field definitions by those entering data into Merlin vary, and this might lead to inconsistent data entry practices. Finally, Merlin does not allow for recording times in less than 1-day increments; thus, shorter intervals for reporting laboratory results could not be assessed.

This analysis did not assess directly the potential effect of ELR on the workload of CHD communicable disease investigators in Florida. However, the implementation of ELR likely will have some effects. For example, most cases of meningococcal disease in Florida are reported quickly to FDOH and intensively investigated under the existing reporting system. Thus, the number of cases of meningococcal disease requiring investigation is not likely to increase with ELR. However, for salmonellosis, shigellosis, and hepatitis A, an increase in reported cases is anticipated with ELR, because all positive cultures and immunoglobulin (IgM) results will be transmitted electronically. Under the existing system, in 2005, 84% of hospitalized salmonellosis patients were recorded in the Merlin database, 73% of hospitalized shigellosis patients, and 52% of hospitalized hepatitis A patients. If ELR captures more cases than currently are entered into Merlin manually, the workload of county and state health staff will increase. For some reportable conditions (e.g., hepatitis A), a large amount of clinical information and additional laboratory data often is required to confirm the diagnosis after a laboratory report is received. Much of this information is not included among the ELR data but is needed to classify the case according to the case definition. The implementation of ELR might cause an increase in the number of preliminary reports that must be investigated, thus increasing workload, without a corresponding increase in the number of confirmed cases (6,7).

ELR is being introduced in Florida in a stepwise fashion, with laboratory facilities brought on incrementally rather than all at once. This is allowing CHDs to assess the effects of ELR on workflow and human resource requirements for various reportable diseases. The analysis in this report suggests the effects of ELR will be disease specific, with differing limitations and challenges for each condition. Under a newly implemented

ELR system, local and state public health officials should be able to 1) monitor timeliness and completeness of reporting, 2) assess workload and workflow, 3) ensure that reporting of high-priority conditions is not adversely affected by ELR, and 4) interact with clinicians in a manner that fosters respect for the clinician-patient relationship and compliance with statemandated reporting requirements. If the number of reported cases increases substantially when ELR is implemented, jurisdictions will need to establish priorities for investigation and follow-up of laboratory reports received (*6*).

References

- Effler P, Ching-Lee M, Bogard A, Ieong MC, Nekomoto T, Jernigan D. Statewide system of electronic notifiable disease reporting from clinical laboratories: comparing automated reporting with conventional methods. JAMA 1999;282:1845–50.
- 2. Overhage JM, Grannis S, McDonald CJ. A comparison of the completeness and timeliness of automated electronic reporting and spontaneous reporting of notifiable conditions. Am J Public Health 2008;98:344–50.
- Jajosky RA, Groseclose SL. Evaluation of reporting timeliness of public health surveillance systems for infectious diseases. BMC Public Health 2004;4:29. Available at http://www.biomedcentral.com/1471-2458/4/29.
- 4. American Academy of Pediatrics. Summaries of infectious diseases. In: Pickering LK, Baker CJ, Long SS, McMillan JA, eds. Red Book: 2006 report of the Committee on Infectious Disease. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006.
- American Public Health Association. Heymann DL, ed. Control of communicable diseases manual. 18th ed. Washington, DC: American Public Health Association; 2004.
- CDC. Effect of electronic laboratory reporting on the burden of Lyme disease surveillance—New Jersey, 2001–2006. MMWR 2008;57:42–5.
- CDC. Positive test results for acute hepatitis A virus infection among persons with no recent history of acute hepatitis—United States, 2002–2004. MMWR 2005;54:453–6.

Update: Influenza Activity – United States, September 28– November 29, 2008

During September 28–November 29, 2008, influenza activity remained low in the United States. Of the few influenza viruses characterized thus far this season, most are antigenically related to the strains included in the 2008–09 influenza vaccine. Oseltamivir-resistant influenza A (H1N1) viruses have been detected, but currently available data are insufficient to predict their prevalence for the 2008–09 season. This report summarizes U.S. influenza activity* since the last update (*I*) and reviews new influenza vaccine recommendations for the current season.

Viral Surveillance

During September 28–November 29, 2008, approximately 150 World Health Organization (WHO) and National Respiratory and Enteric Virus Surveillance System collaborating laboratories in the United States tested 24,657 respiratory specimens for influenza viruses; 365 (1.5%) were positive (Figure 1). Of these, 282 (77.3%) were influenza A viruses, and 83 (22.7%) were influenza B viruses. One hundred twentyeight (45.4%) of the 282 influenza A viruses were subtyped; 112 (87.5%) of these were influenza A (H1) viruses, and 16 (12.5%) were influenza A (H3) viruses. Influenza-positive tests have been reported from 26 states in eight of the nine surveillance regions since September 28.

Antigenic Characterization

WHO collaborating laboratories in the United States are requested to submit a subset of their influenza-positive respiratory specimens to CDC for further antigenic characterization. CDC has antigenically characterized 30 influenza viruses collected by U.S. laboratories during the 2008–09 season, including 20 influenza A (H1N1), three influenza A (H3N2), and seven influenza B viruses. Twenty-seven of the 30 viruses were antigenically related to the components included in the 2008–09 influenza vaccine (A/Brisbane/59/2007-like (H1N1), A/Brisbane/10/2007-like (H3N2), and B/Florida/04/2006like). The other three influenza B viruses belong to the B/Victoria/02/87 lineage.

Antiviral Resistance of Influenza Virus Isolates

With limited influenza activity in the United States, few viruses have been available for antiviral resistance testing. Since September 28, 2008, 39 influenza viruses from 11 states have been tested for antiviral resistance; of the viruses tested, 28 (71.8%) were collected from only two states. Preliminary data show that 24 of the 25 influenza A (H1N1) isolates tested were resistant to oseltamivir; all H1N1 isolates were sensitive to zanamivir. All five influenza A (H3N2) and the nine influenza B isolates tested were sensitive to oseltamivir and zanamivir. Twenty-five influenza A (H1N1) isolates and five influenza A (H3N2) isolates were sensitive to adamantane resistance. All influenza A (H1N1) isolates tested were sensitive to adamantanes, and all influenza A (H3N2) isolates tested were sensitive to adamantanes. The adamantanes are not effective against influenza B viruses.

Currently, data on antiviral resistance, and information on which influenza virus types or subtypes will circulate, are insufficient to provide an indication of the prevalence of antiviral resistance at a national or regional level during this season. CDC has solicited a representative sample of viruses from WHO collaborating laboratories in the United States for resistance testing throughout the season, and more specimens are expected as influenza activity increases.

Novel Influenza A Viruses


One case of human infection with a novel influenza A virus was reported from Texas during the week ending November 15, 2008. A child aged 14 years was infected with swine influenza A (H1N1) in October 2008 after several reported swine exposures. The child recovered from the illness, and no contacts of the child were reported to be ill.


State-Specific Activity Levels

For the week ending November 29, 2008, influenza activity[†] was reported as sporadic in Puerto Rico and 22 states, and one

^{*} The CDC influenza surveillance system collects five categories of information from 10 data sources. Viral surveillance: U.S. World Health Organization collaborating laboratories, the National Respiratory and Enteric Virus Surveillance System, and novel influenza A virus case reporting. Outpatient illness surveillance: U.S. Influenza Sentinel Provider Surveillance Network and the U.S. Department of Veterans Affairs/U.S. Department of Defense BioSense Outpatient Surveillance System. Mortality: 122 Cities Mortality Reporting System and influenza-associated pediatric mortality reports. Hospitalizations: Emerging Infections Program and New Vaccine Surveillance Network. Summary of geographic spread of influenza: state and territorial epidemiologist reports.

[†] Levels of activity are 1) no activity; 2) sporadic: isolated laboratory-confirmed influenza cases or a laboratory-confirmed outbreak in one institution, with no increase in activity; 3) local: increased ILI, or at least two institutional outbreaks (ILI or laboratory-confirmed influenza) in one region with recent laboratory evidence of influenza in that region; virus activity no greater than sporadic in other regions; 4) regional: increased ILI activity or institutional outbreaks (ILI or laboratory-confirmed influenza) in at least two but less than half of the regions in the state with recent laboratory evidence of influenza in those regions; and 5) widespread: increased ILI activity or institutional outbreaks (ILI or laboratory-confirmed influenza) in at least half the regions in the state with recent laboratory evidence of influenza in the state.





* N = 365 (of 24,657 tested).

state (Hawaii) reported local activity. Twenty-seven states and the District of Columbia reported no activity. No states have reported regional or widespread activity this season.

Outpatient Illness Surveillance

Since September 28, 2008, the weekly percentage of outpatient visits for influenza-like illness $(ILI)^{\$}$ reported by approximately 1,500 U.S. sentinel providers in 50 states, New York City, Chicago, and the District of Columbia that comprise the U.S. Outpatient ILI Surveillance Network (ILINet), has ranged from 0.9% to 1.3% (Figure 2). This is below the national baseline of 2.4%. In addition, all nine surveillance regions reported percentages below their respective region-specific baselines.[¶]

Pneumonia- and Influenza-Related Mortality

For the week ending November 29, 2008, pneumonia and influenza (P&I) was reported as an underlying or contributing cause of death for 6.7% of all deaths reported to the 122 Cities Mortality Reporting System. This is below the epidemic threshold of 7.1% for that period. Since September 28, 2008, the weekly percentage of deaths attributed to P&I ranged from 6.0%–6.7%, remaining below the epidemic threshold.**

Influenza-Associated Pediatric Hospitalizations

Pediatric hospitalizations associated with laboratoryconfirmed influenza infections are monitored by two population-based surveillance networks, the Emerging Infections Program (EIP) and the New Vaccine Surveillance Network (NVSN). No influenza-associated pediatric hospitalizations have yet been reported by either network this season.

Influenza-Related Pediatric Mortality

No influenza-related pediatric deaths have been reported for the 2008–09 season.

Reported by: WHO Collaborating Center for Surveillance, Epidemiology, and Control of Influenza. L Brammer, MPH, S Epperson, MPH, L Blanton, MPH, R Dhara, MPH, T Wallis, MS, L Finelli, DrPH, A Fiore, MD, L Gubavera, PhD, J Bresee, MD, A Klimov, PhD, N Cox, PhD, Influenza Div, National Center for Immunization and Respiratory Diseases; S Doshi, MD, EIS Officer, CDC.


Editorial Note: During September 28–November 29, 2008, the United States experienced a low level of influenza activity which is typical for this time of year and similar to the past four influenza seasons. The peak of influenza activity has come

[§] Defined as a temperature of ≥100.0°F (≥37.8°C), oral or equivalent, and cough and/or sore throat, in the absence of a known cause other than influenza.

⁹ The national and regional baselines are the mean percentage of visits for ILI during noninfluenza weeks for the previous three seasons plus two standard deviations. A noninfluenza week is a week during which <10% of specimens tested positive for influenza. National and regional percentages of patient visits for ILI are weighted on the basis of state population. Use of the national baseline for regional data is not appropriate.

^{**} The seasonal baseline proportion of P&I deaths is projected using a robust regression procedure in which a periodic regression model is applied to the observed percentage of deaths from P&I that were reported by the 122 Cities Mortality Reporting System during the preceding 5 years. The epidemic threshold is 1.645 standard deviations above the seasonal baseline.

FIGURE 2. Percentage of visits for influenza-like illness (ILI) reported by the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), by week — United States, September 28–November 29, 2008 and 2006–07 and 2007–08 influenza seasons



* The 2006–07 and 2007–08 seasons reported 52 weeks; therefore, the week 53 data point for those seasons is an average of weeks 52 and 1.

before January in only five of the past 20 seasons; February or March has been the peak month in 11 of those 20 seasons (CDC, unpublished data, 2008). Influenza vaccine first became available in August, allowing persons to be vaccinated before influenza activity began. Vaccination efforts should continue during December given the most common timing of peak influenza activity, and providers should offer influenza vaccine throughout the influenza season (which can persist as late as April or May) to protect as many persons from influenza infection and its complications as possible.

Most of the U.S. influenza viruses identified and characterized thus far in the 2008–09 season are antigenically similar to the components included in the 2008–09 influenza vaccine. However, these viruses were isolated in few states and early in the influenza season; CDC will test more viruses as flu activity increases and more samples become available. The season has not progressed enough to determine which influenza virus type or subtype will predominate this season.

On average, influenza is estimated to cause approximately 226,000 hospitalizations and 36,000 deaths per year in the United States. Annual vaccination remains the best method for preventing influenza and its potentially severe complications. The Advisory Committee on Immunization Practices (ACIP) recently expanded its recommendations for influenza vaccination to include all children aged 6 months–18 years. In addition, influenza vaccine should be administered to other persons at high risk for influenza-related complications, close contacts of those at high risk (including health-care workers), and anyone else who wants to decrease their risk for influenza (*2*).

CDC conducts surveillance for resistance of circulating influenza viruses to licensed antiviral medications: adamantanes (amantadine and rimantadine) and neuraminidase inhibitors (zanamivir and oseltamivir). Antiviral resistance testing is not commercially available to guide clinical management of individual patients. Influenza A (H1N1) viruses that have a genetic mutation conferring oseltamivir resistance appeared and circulated during the 2007-08 Northern Hemisphere influenza season (3), and during the 2008 Southern Hemisphere season, with some Southern Hemisphere countries reporting that a majority of tested A (H1N1) viruses were resistant to oseltamivir (4). To date, oseltamivir-resistant A (H1N1) viruses from all countries that have submitted specimens to CDC have been sensitive to zanamivir, and most have been susceptible to the adamantanes. All tested influenza A (H1N1), influenza A (H3N2), and influenza B viruses have been sensitive to zanamivir. Most recent influenza A (H3N2) viruses circulating worldwide are resistant to adamantanes, and adamantanes are not effective against influenza B infections. The prevalence of oseltamivir resistance this season will depend on the level of influenza activity, the proportion of resistance among influenza A (H1N1) viruses and the proportion of A (H1N1) viruses among all circulating influenza viruses. At this time, too few specimens from a limited geographic area have been tested to accurately estimate either proportion; thus the prevalence of oseltamivir resistance for the 2008-09 season cannot be estimated accurately.

Enhanced surveillance for oseltamivir-resistant viruses is ongoing at CDC. Alternatives for antiviral treatment in the context of widely circulating oseltamivir-resistant viruses have been suggested. These treatment options, which might include preferential use of zanamivir or therapy with a combination of antivirals for certain patients, have been outlined in the ACIP 2008 influenza recommendations.^{††} Currently, the neuraminidase inhibitors oseltamivir and zanamivir remain the recommended medications for treatment and chemoprophylaxis of influenza.

Clinicians should remain alert for changes in recommendations that might occur as the 2008–09 influenza season progresses. Recommendations regarding the use of antiviral medications might be revised if surveillance data indicate a substantial and widespread increase in the prevalence of oseltamivir-resistant influenza viruses in the United States.

Vaccination remains the cornerstone of influenza prevention efforts. Influenza vaccination can prevent influenza infections from strains that are sensitive or resistant to antiviral medications; the influenza A (H1N1) viruses found to be oseltamivir resistant are antigenically similar to the components included

^{††} Available at http://www.cdc.gov/flu/professionals/antivirals/resistance.htm.

in the 2008–09 vaccine. December 8–14 is National Influenza Vaccination Week. Health-care providers are encouraged to take advantage of heightened awareness of the benefits of influenza vaccination and to increase vaccination efforts during this week to reach persons who have not yet been vaccinated.

CDC continues to conduct surveillance to provide up-todate recommendations regarding prevention and treatment of influenza. Influenza surveillance reports for the United States are posted online weekly during October–May and are available at http://www.cdc.gov/flu/weekly/fluactivity.htm. Additional information regarding influenza viruses, influenza surveillance, influenza vaccine, and avian influenza is available at http://www.cdc.gov/flu.

Acknowledgments

This report is based, in part, on data contributed by participating state and territorial health departments and state public health laboratories, WHO collaborating laboratories, National Respiratory and Enteric Virus Surveillance System collaborating laboratories, the U.S. Influenza Sentinel Provider Surveillance System, and the 122 Cities Mortality Reporting System; WHO National Influenza Centers, WHO Global Influenza Programme, Geneva, Switzerland; A Kelso, PhD, I Barr, PhD, WHO Collaborating Center for Reference and Research on Influenza, Parkville, Australia; A Hay, PhD, WHO Collaborating Center for Reference and Research on Influenza, National Institute of Medical Research, London, England; and M Tashiro, MD, WHO Collaborating Center for Reference and Research on Influenza, National Institute of Infectious Diseases, Tokyo, Japan.

References

- 1. CDC. Influenza activity—United States and worldwide, May 18–September 19, 2008. MMWR 2008;57:1046–9.
- CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR 2008;57(No. RR-7).
- CDC. Influenza activity—United States and worldwide, 2007–08 season. MMWR 2008;57:692–7.
- World Health Organization. Influenza A(H1N1) virus resistance to oseltamivir—2008 influenza season, southern hemisphere. Geneva, Switzerland: World Health Organization; 2008. Available at http://www.who.int/csr/ disease/influenza/H1N1200801013.pdf.

Notice to Readers

Publication of World Report on Child Injury Prevention

Child injuries are a growing global public health problem. Worldwide each year, approximately 10-30 million persons aged <18 years are injured, and 875,000 die from their injuries (1,2). Moreover, 95% of these injuries occur in low- and middle-income countries (1). In 2005, the World Health Organization (WHO) and United Nations Children's Fund (UNICEF) called for an expanded global effort to prevent child injury (2).

On December 10, 2008, WHO and UNICEF released their *World Report on Child Injury Prevention*. The report examines the five major mechanisms of child injuries: road traffic injuries, drownings, burns, falls, and poisonings (*3*). Each mechanism is reviewed according to its epidemiology, known risk factors, existing interventions and their effectiveness, and strategies to prevent or manage the particular type of injury. The report documents what is known about child and adolescent injuries worldwide and how these injuries can be prevented.

In the United States each year, approximately 12,000 deaths and an estimated 9.2 million nonfatal unintentional injuries are reported among persons aged \leq 19 years (4); unintentional injuries are the leading cause of death among those aged 1–19 years (4,5). Creating a safe environment, adopting and enforcing stringent safety laws, improving product safety, educating parents, and encouraging behavior change are all important in the prevention of injuries in children. Information regarding U.S. data and efforts to prevent child injuries, including the CDC Childhood Injury Report, is available at http://www.cdc. gov/safechild. Other tools at this site include fact sheets, podcasts, and state-specific data on the leading causes of child and adolescent injury, and how these injuries can be prevented.

References

- Mock C, Peden M, Hyder AA, Butchart A, Krug E. Child injuries and violence: the new challenge for child health. Bull World Health Organ 2008;86:420.
- World Health Organization, United Nations Children's Fund. Child and adolescent injury prevention: a global call to action. Geneva, Switzerland: World Health Organization, United Nations Children's Fund; 2005. Available at http://whqlibdoc.who.int/publications/2005/9241593415_ eng.pdf.
- World Health Organization, United Nations Children's Fund. World report on child injury prevention. Geneva, Switzerland: World Health Organization, United Nations Children's Fund; 2008. Available at http:// www.who.int/violence_injury_prevention/child/injury/world_report/en/ index.html.
- CDC. CDC childhood injury report: patterns of unintentional injuries among 0–19 year olds in the United States, 2000–2006. Atlanta, GA: US Department of Health and Human Services, CDC; 2008.
- CDC. Fatal injuries among children by race and ethnicity—United States, 1999–2002. MMWR 2007;56(No. SS-5).

Notice to Readers

Pre-Beta Version of Open Source Epi Info Released

CDC has released a pre-beta version of the Epi Info[™] Community Edition for developers and information technology professionals who wish to contribute enhancements and features. This release represents the beginning of a rewrite of the Epi Info suite of tools into the C#.net development environment. CDC is emphasizing increased collaboration and open development methods to increase the pace of innovation in public health informatics. The transition to open source is expected to benefit the global community by enabling Epi Info projects to receive broader, worldwide participation and open collaboration.

Epi Info Community Edition and its source code are available at http://www.codeplex.com/epiinfo. This release includes support for the nonproprietary database format, MySQL, compatible on Windows and Linux operating systems, and the more common formats of Microsoft Access and Microsoft SQL Server. A stable distribution of Epi Info Version 3.5.1 remains available at http://www.cdc.gov/epiinfo. Additional information about either distribution is available via the Epi Info help desk at epiinfo@cdc.gov.




TABLE 1. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending December 6, 2008 (49th week)*


	Current	Cum	5-year weekly	repo		tal cas or prev	ious y	ears	
Disease	week	2008	average [†]	2007	2006	2005	2004	2003	States reporting cases during current week (No.)
Anthrax	—	_	_	1	1	_	_	_	
Botulism:									
foodborne	_	12	1	32	20	19	16	20	
infant	—	91	2	85	97	85	87	76	
other (wound & unspecified)	_	21	1	27	48	31	30	33	
Brucellosis	_	82	2	131	121	120	114	104	
Chancroid	_	30	1	23	33	17	30	54	
Cholera	_	2	0	7	9	8	6	2	
Cyclosporiasis [§]	2	121	2	93	137	543	160	75	FL (1), TX (1)
Diphtheria Domestic arboviral diseases ^{§,¶} :	_	1	_	_	_	_	_	1	
		40	0	EE	67	00	110	108	
California serogroup eastern equine	_	43 2	0	55 4	67 8	80 21	112 6	108	
Powassan	_	1		7	1	1	1		
St. Louis	_	8	_	9	10	13	12	41	
western equine	_		_	9	10	15	12	41	
Ehrlichiosis/Anaplasmosis ^{§,**} :									
Ehrlichia chaffeensis	5	799	7	828	578	506	338	321	MN (1), NC (3), FL (1)
Ehrlichia ewingii		799		520					(1), 10 (0), 1 E (1)
Anaplasma phagocytophilum	7	433	12	834	646	786	537	362	ME (1), NY (1), MN (5)
undetermined	_	64	1	337	231	112	59	44	
Haemophilus influenzae, ^{††}		04		007	201	112	00		
invasive disease (age <5 yrs):									
serotype b	1	26	0	22	29	9	19	32	MN (1)
nonserotype b	1	152	2	199	175	135	135	117	AZ (1)
unknown serotype	4	174	4	180	179	217	177	227	OH (1), NE (1), NC (1), FL (1)
Hansen disease§	_	67	2	101	66	87	105	95	0(.),= (.),0 (.), .= (.)
Hantavirus pulmonary syndrome [§]	_	14	1	32	40	26	24	26	
Hemolytic uremic syndrome, postdiarrheal§	3	210	3	292	288	221	200	178	CT (1), FL (1), CA (1)
Hepatitis C viral, acute	9	763	18	849	766	652		1,102	NY (2), PA (1), IN (2), FL (2), WA (1), CA (1)
HIV infection, pediatric (age <13 years)§§	_	_	4	_		380	436	504	(n) (n) (n) (n) (n) (n)
Influenza-associated pediatric mortality ^{§,¶¶}	_	90	0	77	43	45	_	Ν	
Listeriosis	11	597	14	808	884	896	753	696	NY (3), PA (2), OH (1), FL (2), WA (2), CA (1)
Measles***	1	134	1	43	55	66	37	56	OH (1)
Meningococcal disease, invasive ^{†††} :									
A, C, Y, & W-135	2	250	5	325	318	297	_	_	IN (1), NC (1)
serogroup B	—	142	3	167	193	156	_	_	
other serogroup	—	30	0	35	32	27	_	_	
unknown serogroup	7	559	11	550	651	765	_	_	OH (1), MO (1), MS (1), AR (2), TX (1), CA (1)
Mumps	1	359	18	800	6,584	314	258	231	NY (1)
Novel influenza A virus infections	—	1	—	4	N	N	N	N	
Plague	—	1	0	7	17	8	3	1	
Poliomyelitis, paralytic	—	—	_	—	_	1	—	—	
Polio virus infection, nonparalytic§	—	—	_	_	N	N	N	N	
Psittacosis§		11	0	12	21	16	12	12	
Qfever ^{§,§§§} total:	2	109	1	171	169	136	70	71	
acute	2	97	_	_	_	_	_	_	CO (1), CA (1)
chronic	_	12	_		_	_	_	_	
Rabies, human	—		0	1	3	2	7	2	
Rubella ¹¹¹¹	—	17	0	12	11	11	10	7	
Rubella, congenital syndrome	—	—	—	—	1	1	_	1	
SARS-CoV ^{§,****}	—	—	—	—	_	_	_	8	
Smallpox [§]			_						
Streptococcal toxic-shock syndrome [§]	1	121	2	132	125	129	132	161	IN (1)
Syphilis, congenital (age <1 yr)	_	210	8	430	349	329	353	413	
Fetanus Favia shaak sundrama (stanbulasasas))§	_	12	1	28	41	27	34	20	NY (1) CO (1)
Toxic-shock syndrome (staphylococcal)§	2	62	2	92	101	90	95	133	NY (1), CO (1)
Trichinellosis	_	6	0	5	15	16	5	6	CA (1)
Tularemia	1	94	2	137	95	154	134	129	CA (1)
Typhoid fever	2	366	5	434	353	324	322	356	FL (1), TN (1)
Vancomycin-intermediate Staphylococcus aureus§		30	0	37	6	2	-	N	
Vancomycin-resistant <i>Staphylococcus aureus</i> §		400	0	2	1	3	1 N	N	OH (1) MN (1) NC (1) CA (1) CA (1)
Vibriosis (noncholera Vibrio species infections)§	5	420	3	447	N	N	N	N	OH (1), MN (1), NC (1), GA (1), CA (1)

See Table 1 footnotes on next page.

TABLE 1. (Continued) Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending December 6, 2008 (49th week)*

- -: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts.
- * Incidence data for reporting year 2008 are provisional, whereas data for 2003, 2004, 2005, 2006, and 2007 are finalized.
- [†] Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. Additional information is available at http://www.cdc.gov/epo/dphsi/phs/files/5yearweeklyaverage.pdf.
- § Not notifiable in all states. Data from states where the condition is not notifiable are excluded from this table, except in 2007 and 2008 for the domestic arboviral diseases and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm.
- Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II.
- ** The names of the reporting categories changed in 2008 as a result of revisions to the case definitions. Cases reported prior to 2008 were reported in the categories: Ehrlichiosis, human monocytic (analogous to *E. chaffeensis*); Ehrlichiosis, human granulocytic (analogous to *Anaplasma phagocytophilum*), and Ehrlichiosis, unspecified, or other agent (which included cases unable to be clearly placed in other categories, as well as possible cases of *E. ewingii*).
- ⁺⁺ Data for *H. influenzae* (all ages, all serotypes) are available in Table II.
- ^{§§} Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting influences the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data management system is completed. Data for HIV/AIDS, when available, are displayed in Table IV, which appears quarterly.
- 11 Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. There are no reports of confirmed influenza-associated pediatric deaths for the current 2008-09 season.
- *** The one measles case reported for the current week was indigenous.
- ⁺⁺⁺ Data for meningococcal disease (all serogroups) are available in Table II.
- §§§ In 2008, Q fever acute and chronic reporting categories were recognized as a result of revisions to the Q fever case definition. Prior to that time, case counts were not differentiated with respect to acute and chronic Q fever cases.
- 111 No rubella cases were reported for the current week.
- **** Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases.

FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals December 6, 2008, with historical data



* Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

Notifiable Disease Data Team and	1 122 Cities Mortality Data Team													
Patsy A. Hall														
Deborah A. Adams Willie J. Anderson Lenee Blanton	Rosaline Dhara Michael S. Wodajo Pearl C. Sharp													

(4911 week)			Chlamyd	ia [†]				Cryptosporidiosis							
		Prev					Prev					Prev			
Reporting area	Current week	52 w	Max	Cum 2008	Cum 2007	Current week	52 we	Max	Cum 2008	Cum 2007	Current week	52 v	veek Max	Cum 2008	Cum 2007
United States	12,903	21,242	28,892		1032955	166	122	341	6,391	7,294	61	98	427	7,191	10,739
New England Connecticut Maine [§] Massachusetts New Hampshire Rhode Island [§] Vermont [§]	711 97 63 348 26 153 24	707 202 51 331 41 54 14	1,516 1,093 72 624 64 208 52	34,941 10,489 2,450 16,359 1,988 2,908 747	33,496 9,865 2,404 15,271 1,953 3,005 998	N N N	0 0 0 0 0 0	1 0 0 1 0 0	1 N N 1 N	2 N N 2 N	 	4 0 1 1 0 1	40 38 6 9 4 2 7	291 38 42 91 56 7 57	326 42 53 128 47 11 45
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	1,294 193 610 491	2,773 404 542 994 805	4,968 535 2,177 3,415 1,050	137,095 19,378 25,831 52,976 38,910	135,116 20,373 26,258 48,194 40,291	N N N N	0 0 0 0	0 0 0 0		N N N N	7 3 4	12 0 4 2 5	34 2 17 6 15	683 26 254 98 305	1,327 67 236 98 926
E.N. Central Illinois Indiana Michigan Ohio Wisconsin	1,232 430 582 11 209	3,516 1,059 371 837 821 328	4,373 1,711 706 1,226 1,261 612	162,986 46,428 19,325 41,474 40,039 15,720	169,497 51,119 19,853 34,947 45,012 18,566	1 N 	1 0 0 0 0	3 0 3 1 0	39 N 29 10 N	35 N 24 11 N	20 	24 2 3 4 6 8	122 7 41 13 59 46	1,882 105 180 248 669 680	1,840 197 107 203 553 780
W.N. Central Iowa Kansas Minnesota Missouri Nebraska [§] North Dakota South Dakota	1,053 189 219 — 430 151 — 64	1,261 168 178 265 479 77 32 55	1,696 240 529 373 566 244 65 85	60,919 8,553 8,701 12,247 23,071 4,112 1,484 2,751	59,867 8,251 7,763 12,826 22,105 4,827 1,651 2,444	Z Z Z Z Z	0 0 0 0 0 0 0	77 0 77 2 0 0 0	4 N 4 N N N	8 N 	11 1 6 2 1 - 1	15 4 5 3 2 0 1	71 30 15 13 8 51 9	932 271 82 223 162 111 7 76	1,563 606 143 273 176 172 27 166
S. Atlantic Delaware District of Columbia Florida Georgia Maryland [§] North Carolina South Carolina [§] Virginia [§] West Virginia	2,713 88 108 1,172 1 722 621 1	3,589 67 127 1,362 247 444 0 448 619 59	7,609 150 207 1,571 1,338 696 4,783 3,045 1,059 101	176,669 3,521 6,360 64,966 18,097 21,026 5,901 24,662 29,226 2,910	200,478 3,262 5,703 54,302 40,037 21,474 24,659 24,671 23,372 2,998	Z Z Z Z Z Z Z	0 0 0 0 0 0 0 0 0 0	1 0 0 1 0 0 0 0	4 1 N N 3 N N N N	5 2 N N 3 N N N N N	12 	18 0 7 4 1 0 1 1 0	46 2 35 13 4 16 4 4 3	932 11 10 446 222 38 67 49 68 21	1,222 20 3 642 226 34 121 81 81 81 11
E.S. Central Alabama [§] Kentucky Mississippi Tennessee [§]	1,775 243 917 615	1,554 453 236 369 527	2,302 560 373 1,048 790	77,116 19,734 11,477 19,698 26,207	78,146 23,914 8,186 20,450 25,596	N N N	0 0 0 0	0 0 0 0		N N N N	 	3 1 0 1	9 6 4 2 6	154 64 32 17 41	607 120 248 102 137
W.S. Central Arkansas [§] Louisiana Oklahoma Texas [§]	551 340 211 —	2,777 278 404 186 1,906	4,426 455 775 392 3,923	131,162 13,200 20,082 7,668 90,212	117,875 9,323 18,493 11,936 78,123	N N N	0 0 0 0	1 0 1 0 0	3 N 3 N N	3 N 3 N N	2 _2	5 0 1 1 2	152 6 5 16 137	1,434 37 54 130 1,213	435 60 62 117 196
Mountain Arizona Colorado Idaho [§] Montana [§] Nevada [§] New Mexico [§] Utah Wyoming [§]	1,266 235 372 88 5 188 269 109	1,266 467 212 63 58 178 137 111 30	1,811 651 589 314 363 416 561 253 58	61,428 22,190 10,510 3,768 2,671 8,605 7,353 4,951 1,380	69,551 23,392 16,381 3,483 2,358 9,098 8,504 5,208 1,127	137 136 N N 1 	86 86 0 0 1 0 0 0	170 168 0 0 0 6 3 3 1	4,209 4,128 N N 45 28 6 2	4,606 4,455 N N 65 22 61 3		9 1 1 1 0 1 0 0	37 9 12 5 6 1 23 6 4	504 87 108 63 41 1 149 38 17	2,892 51 207 461 66 36 123 1,894 54
Pacific Alaska California Hawaii Oregon [§] Washington	2,308 47 1,662 46 267 286	3,703 85 2,898 104 191 367	4,676 129 4,115 160 631 634	173,704 4,146 136,649 4,962 10,082 17,865	168,929 4,567 132,195 5,384 9,161 17,622	28 N 28 N N N	33 0 33 0 0 0	217 0 217 0 0 0	2,131 N 2,131 N N N	2,635 N 2,635 N N N	9 6 1 2	8 0 5 0 1 2	29 1 14 1 4 16	379 3 231 2 52 91	527 3 277 6 125 116
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands		0 4 117 12	20 612 23	73 123 6,392 502	95 787 7,346 150	N N	0 0 0 0	0 0 0 0	N N	N N	N N	0 0 0 0	0 0 0 0	N N	N N

TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending December 6, 2008, and December 8, 2007 (49th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting year 2008 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly. † Chlamydia refers to genital infections caused by *Chlamydia trachomatis*. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

			Giardias	is				Gonorrhe	ea		Haemophilus influenzae, invasive All ages, all serotypes [†]				
			/ious					vious				Previ			
Reporting area	Current week	Med	/eeks Max	Cum 2008	Cum 2007	Current week	Med	weeks Max	Cum 2008	Cum 2007	Current week	52 we	еекs Max	Cum 2008	Cum 2007
United States	184	306	1,158	15,990	17,445	3,361	5,944	8,913	278,655	333,249	26	48	173	2,353	2,271
New England	6	24	49	1,186	1,397	73	101	227	4,912	5,309	1	3	12	137	175
Connecticut Maine [§]	6	6 3	11 12	291 177	351 185	22 2	50 2	199 6	2,383 91	2,033 114	1	0 0	9 2	41 16	45 13
Massachusetts New Hampshire	_	9 2	17 11	343 142	579 33	39 2	39 2	90 6	2,018 96	2,580 135	_	1 0	5 1	57 9	86 18
Rhode Island§	_	1	8	76	80	6	6	13	295	386	—	Ō	1	6	9
Vermont [§] Mid. Atlantic		3 59	13 131	157 3,002	169 3,035	2 298	0 621	5 1,028	29 30,477	61 34,215	6	0 10	3 31	8 465	4 442
New Jersey	—	7	14	302	389	54	95	167	4,676	5,753	_	1	7	71	66
New York (Upstate) New York City	33 4	23 15	111 28	1,142 757	1,109 816	108	120 179	545 636	5,653 9,885	6,544 9,882	3	3 1	22 6	142 81	128 99
Pennsylvania	12	15	45	801	721	136	214	394	10,263	12,036	3	4	8	171	149
E.N. Central Illinois	25	46 10	79 24	2,326 512	2,744 837	527	1,228 364	1,647 589	57,861 16,067	68,688 19,218	6	7 2	28 7	341 102	347 110
Indiana	N	0	0	N	N	143	147	284	7,704	8,457	1	1	20	66	57
Michigan Ohio	6 19	11 16	21 31	536 849	586 781	318 4	320 297	657 531	15,638 14,200	14,516 20,080	5	0 2	3 6	20 126	29 97
Wisconsin		8	19	429	540	62	89	175	4,252	6,417	_	1	2	27	54
W.N. Central lowa	15 2	28 6	621 18	1,906 306	1,413 293	265 34	316 29	425 48	15,440 1,476	18,416 1,823	_2	3 0	24 1	185 2	134 1
Kansas Minnesota	2	3 0	11 575	156 666	174 168	66	41 56	130 92	2,171 2,650	2,171 3,295	1	0	3 21	16 57	11 59
Missouri	5	8	22	431	500	123	149	199	7,471	9,417		1	6	69	39
Nebraska [§] North Dakota	6	4 0	10 36	201 23	153 24	30	24 2	47 6	1,244 91	1,358 111	1	0 0	2 3	28 13	18 6
South Dakota	_	2	10	123	101	12	7	15	337	241	—	0	0	—	—
S. Atlantic Delaware	38	54 1	87 3	2,631 39	2,898 40	959 25	1,186 19	3,072 44	59,344 973	78,804 1,225	9	12 0	29 2	632 7	562 8
District of Columbia	 33	1 23	5 57	52 1,259	73 1,202	57 393	48 448	101	2,449 21,500	2,252 22,057	6	0 3	2 10	11 177	3 152
Florida Georgia	_	9	27	511	653	393	123	549 560	6,912	16,546	_	2	9	134	112
Maryland§ North Carolina	2 N	5 0	12 0	237 N	253 N	_	116 0	206 1,949	5,649 2,638	6,365 13,838	2 1	2 1	6 9	90 73	83 51
South Carolina§	3	2 8	6	123 356	116	199 280	180	830	8,844	9,618	_	1	7	47 73	51
Virginia [§] West Virginia	_	0 1	39 5	356 54	513 48	280	177 14	486 26	9,697 682	6,019 884	_	1 0	6 3	20	74 28
E.S. Central	2	9	21	441	538	526	552	837	27,400	30,458	_	2	8	119	132
Alabama ^ş Kentucky	1 N	5 0	12 0	247 N	249 N	86	175 90	250 153	7,825 4,338	10,284 3,204	_	0 0	2 1	19 2	28 9
Mississippi Tennessee§	N 1	0 4	0 13	N 194	N 289	257 183	130 161	401 297	6,928 8,309	7,844 9,126	_	0 2	2 6	13 85	9 86
W.S. Central	4	7	41	405	412	175	953	1,355	44,534	48,919	_	2	29	97	95
Arkansas [§] Louisiana	1	3 2	8 10	132 120	144 134	90 85	84 169	167 317	4,267 8,552	3,992 10,655	_	0 0	3 2	10 8	9 9
Oklahoma	3	2	35	153	134	—	63	124	2,903	4,602	_	1	21	71	67
Texas [§] Mountain	N 19	0 28	0 60	N 1,393	N 1,759	 154	633 210	1,102 338	28,812 9,999	29,670 13,087	2	0 5	3 14	8 262	10 246
Arizona	4	2	8	129	186	43	64	109	3,119	4,773	1	2	11	105	86
Colorado Idaho [§]	7	11 3	27 14	528 183	553 198	52 6	58 3	100 13	2,900 171	3,210 256	1	1 0	4 4	53 12	56 8
Montana [§] Nevada [§]	3 1	1	9 8	80 88	107 136	23	2 39	10 130	103 1,968	112 2,266	_	0 0	1 2	2 14	2 12
New Mexico§	—	1	7	83	112	22	24	104	1,200	1,639	_	0	4	34	39
Utah Wyoming§	4	5 0	22 3	278 24	424 43	8	10 2	36 9	426 112	755 76	_	1 0	6 2	38 4	38 5
Pacific	26	53	185	2,700	3,249	384	602	746	28,688	35,353	_	2	7	115	138
Alaska California	2 24	2 35	10 91	96 1,766	77 2,181	6 306	10 506	24 657	469 23,849	533 29,558	_	0 0	2 3	16 25	15 46
Hawaii Oregon [§]	_	1 8	4 18	40 425	73 441	5 31	11 23	22 48	540 1,179	629 1,160	_	0 1	2 4	19 52	11 63
Washington	—	8	87	373	477	36	54	90	2,651	3,473	_	0	3	3	3
American Samoa C.N.M.I.	_	0	0	_	_	_	0	1	3	3	_	0	0	_	_
Guam	_	0	0	_	2	_	1	15	73	127	_	0	0	_	1
Puerto Rico U.S. Virgin Islands	_	2 0	13 0	150	363	_	5 2	25 6	254 93	300 39	N	0	0 0	N	2 N
		<u> </u>													

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 6, 2008, and December 8, 2007 (49th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Med * Incidence data for reporting year 2008 are provisional. † Data for *H. influenzae* (age <5 yrs for serotype b, nonserotype b, and unknown serotype) are available in Table I. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

MMWR

<u> </u>				Hepat	itis (viral,	acute), by	type†								
			Α					В					egionellos	sis	
	Current		vious veeks	C	C	Current		vious veeks	C	C	Current		ious eeks	C	C
Reporting area	Current week	Med	Max	Cum 2008	Cum 2007	Current week	Med	Max	Cum 2008	Cum 2007	Current week	Med	Max	Cum 2008	Cum 2007
United States	13	48	171	2,244	2,702	34	68	259	3,212	4,089	30	44	140	2,564	2,486
New England Connecticut	_	2 0	7 4	101 26	128 25	_	1 0	7 7	60 23	121 38	3 3	2 0	16 5	125 41	150 38
Maine§	_	0	2	11	5	_	0	2	11	15		0	2	9	9
Massachusetts New Hampshire	_	0 0	5 2	38 12	65 12	_	0	1 2	9 11	42 5	_	0 0	3 5	13 27	47 8
Rhode Island§	_	0	2	12	13	_	0	1	4	16	_	0	14	30	39
Vermont [§] Mid. Atlantic	2	0 6	1 12	2 284	8 432	2	0 9	1 14	2 398	5 533	 14	0 13	1 58	5 876	9 800
New Jersey	_	1	4	57	120	_	2	7	111	155	—	1	7	79	112
New York (Upstate) New York City	1	1 2	6 6	60 101	71 151	1	1 2	4 6	61 86	84 113	4	5 2	19 12	315 110	218 178
Pennsylvania	1	1	6	66	90	1	3	8	140	181	10	6	33	372	292
E.N. Central Illinois	3	6 1	16 10	292 85	326 113	1	7 1	13 5	365 88	432 126	2	10 1	40 7	537 66	561 106
Indiana	—	0	4	21	27	1	1	6	47	54	—	1	7	49	58
Michigan Ohio	3	2 1	7 4	109 48	92 65	_	2 2	6 8	117 107	114 118	2	2 4	16 18	147 257	164 199
Wisconsin	—	0	2	29	29		0	1	6	20	_	0	3	18	34
W.N. Central Iowa	_	5 1	29 7	241 105	166 44	1	2 0	9 2	97 14	110 25	_2	2 0	9 2	117 15	110 11
Kansas Minnesota	_	0 0	3 23	14 36	11 68	_	0 0	3 5	7 10	8 20	2	0 0	1 4	2 23	10 28
Missouri	_	1	3	42	20	_	1	4	56	38		1	4 5	54	43
Nebraska [§] North Dakota	_	0 0	5 2	40	17	1	0 0	2 1	9 1	12	_	0 0	4 2	20	14
South Dakota	_	ŏ	1	4	6	_	Ő	Ó	_	7	—	Ő	1	3	4
S. Atlantic Delaware	5	7 0	15 1	359 7	457 8	13	17 0	60 3	826 10	941 14	4	9 0	28 2	437 12	413 11
District of Columbia	U	0	0	U	U	U	0	0	U	U		0	2	15	15
Florida Georgia	4	2 1	8 4	140 45	145 65	8	6 3	12 6	318 131	321 144	1	3 0	7 4	140 32	140 38
Maryland [§] North Carolina	1	1 0	3 9	39 60	71 60	1 4	2 0	4 17	77 78	107 124	3	2 0	10 7	113 36	80 44
South Carolina§	_	0	3	17	18	_	1	6	57	61	_	0	2	12	17
Virginia [§] West Virginia	_	1 0	5 2	46 5	81 9	_	2 1	16 30	100 55	122 48	_	1 0	6 3	56 21	51 17
E.S. Central	_	1	9	76	103	7	7	13	352	359	_	2	10	108	96
Alabama [§] Kentucky	_	0 0	4 3	12 29	20 20	4	2 2	6 5	97 88	123 73	_	0 1	2 4	15 53	11 47
Mississippi	—	0	2	5	8	1	1	3	44	37	—	Ó	1	1	_
Tennessee [§] W.S. Central	_	0 4	6 55	30 188	55 255	2 5	3 12	8 131	123 591	126 893	_	1 1	5 23	39 70	38 130
Arkansas§	_	0	1	5	12		0	4	30	69	_	0	2	11	15
Louisiana Oklahoma	_	0	1 3	10 7	27 10	4	1 2	4 22	73 109	95 127	_	0 0	2 6	9 10	6 6
Texas§	—	3	53	166	206	1	7	107	379	602	—	1	18	40	103
Mountain Arizona	1	4 2	12 11	195 99	216 144	1	4 1	10 5	181 63	204 80	1	2 0	7 2	77 20	105 37
Colorado	_	0	3	35	24	—	0	3	30	35	_	0	2	10	21
Idaho ^s Montana [§]	_	0 0	3 1	18 1	8 9	_	0 0	2 1	8 2	14	_	0 0	1	3 4	6 3
Nevada [§] New Mexico [§]	—	0 0	3 3	9 17	11 11	1	1 0	3 2	33 11	46 12	_	0 0	2 1	10 7	9 10
Utah	_	0	2	13	6	_	0	5	30	12	_	0	2	23	16
Wyoming [§]	_	0	1	3	3		0	1	4	5	_	0	0		3
Pacific Alaska		11 0	51 1	508 3	619 4	4	7 0	30 2	342 9	496 9		4 0	18 1	217 2	121
California Hawaii	2	9 0	42 2	417 17	531 7	3	5 0	19 1	243 7	364 16	4	3 0	14 1	175 8	88 2
Oregon§	_	0	3	25	28	_	1	3	39	57	_	0	2	15	12
Washington American Samoa	_	1 0	7 0	46	49	1	1 0	9 0	44	50 14	N	0 0	3 0	17 N	19 N
C.N.M.I.	_	_	_	_	_	_	_	_	_	_	—	_	_	IN	_
Guam Puerto Rico	_	0 0	0 4	17	62	_	0 0	1 5	 39	2 84	_	0 0	0 1	1	4
U.S. Virgin Islands	_	Ő	0			_	0	0		_	_	0	0	_	_

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 6, 2008, and December 8, 2007 (49th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. U: Unavailable. —: No reported cases. N: Not notific * Incidence data for reporting year 2008 are provisional. † Data for acute hepatitis C, viral are available in Table I.

§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

1338

		L	yme disea	ise				Malaria			Me	eningococ Al	cal disea I serotyp		/e [†]
			vious				Prev					Prev			
Reporting area	Current week	52 v	weeks Max	Cum 2008	Cum 2007	Current week	52 w Med	eeks Max	Cum 2008	Cum 2007	Current week	52 we	eeks Max	Cum 2008	Cum 2007
United States	355	370	1,450	24,874	25,669	12	22	136	991	1,225	9	18	53	981	990
New England	5	46	259	3,580	7,704	_	0	35	33	58	_	0	3	22	43
Connecticut Maine [§]	5	0 2	16 73	815	3,036 506	_	0	27 0	11	3 8	_	0 0	1	1 6	6 7
Massachusetts	_	12	114	1,039	2,965	—	0	2	14	34	—	0	3	15	20
New Hampshire Rhode Island [§]	_	11 0	139 0	1,381	886 177	_	0	1 8	4	9	_	0	0	_	3 3
Vermont§	_	2	40	345	134	_	0	1	4	4	_	0	1	_	4
Mid. Atlantic New Jersey	275	226 32	1,012 209	14,553 2,743	10,589 3,072	3	4	14 2	230	375 68	_	2 0	6 2	112 10	120 18
New York (Upstate)	239	68	453	5,116	3,188	2	Õ	7	30	69	_	0	3	29	35
New York City Pennsylvania	36	0 74	7 530	30 6,664	413 3,916	1	3 1	10 3	161 39	198 40	_	0 1	2 5	26 47	20 47
E.N. Central	5	9	139	1,256	2,081	_	2	7	126	135	2	3	9	161	158
Illinois	_	0	9	75	149	_	1	6	57	61	_	1	4 4	54	58
Indiana Michigan	1	0 1	8 11	40 97	51 51	_	0 0	2 2	5 17	10 20	1	0	4 3	26 28	28 25
Ohio Wisconsin	4	1 7	5 125	47 997	32 1,798	_	0	3 3	29 18	27 17	1	0	4 2	39 14	35 12
W.N. Central	48	8	740	1.229	657	_	1	9	64	55	1	2	8	91	69
Iowa	_	1	8	82	122	_	Ö	3	8	3	_	0	3	18	15
Kansas Minnesota	48	0 1	1 731	5 1,082	8 507	_	0 0	2 8	9 25	3 29	_	0 0	1 7	5 24	5 22
Missouri	—	0	4	43	10	—	0	4	14	8	1	0	3	26	17
Nebraska [§] North Dakota	_	0 0	2 9	13 1	7 3	_	0 0	2 1	8	7 4	_	0 0	1 1	12 3	5 2
South Dakota	_	0	1	3	_	_	0	0	_	1	_	0	1	3	3
S. Atlantic Delaware	19 5	66 12	187 37	3,819 730	4,375 697	_2	4 0	15 1	253 3	247 4	1	3 0	10 1	146 2	166 1
District of Columbia	1	2	11	162	116	_	0	2	4	2	—	0	0	_	_
Florida Georgia	2	1 0	10 3	106 22	28 11	2	1 1	7 5	58 49	52 37	_	1 0	3 2	49 16	62 24
Maryland§	7 4	30 0	127 7	1,902 48	2,504 49	—	1 0	6 7	63 27	69 21	_	0	4 3	17 13	19 22
North Carolina South Carolina§	4	0	2	40	49 29	_	0	1	9	7	1	0	3	22	16
Virginia [§] West Virginia	_	11 1	68 11	753 74	863 78	_	1 0	7 0	40	54 1	_	0	2 1	22 5	20 2
E.S. Central	1	0	5	46	51	_	0	2	20	37	1	1	6	51	49
Alabama§	_	0	3	10	13	—	Ō	1	4	6	_	0	2	10	9
Kentucky Mississippi	_	0 0	2 1	5 1	6 1	_	0 0	1	5 1	9 2	1	0 0	2 2	8 12	12 11
Tennessee§	1	0	3	30	31	—	0	2	10	20	_	0	3	21	17
W.S. Central Arkansas [§]	_	2 0	11 0	97	77 1	2	1 0	64 0	76	86 2	3 2	2 0	13 2	108 14	95 9
Louisiana	_	0	1	3	2	_	0	1	3	14	—	0	3	22	25
Oklahoma Texas [§]	_	0 2	1 10	94	74	2	0 1	4 60	4 69	5 65	1	0 1	5 7	17 55	16 45
Mountain	_	0	4	41	45	_	1	3	30	63	_	1	4	50	64
Arizona Colorado	_	0 0	2 2	8 7	_2	_	0	2 1	14 4	12 23	_	0	2 1	9 14	12 21
Idaho§	—	0	2	9	9	—	0	1	3	5	—	0	1	4	7
Montana [§] Nevada [§]	_	0 0	1 2	4 4	4 15	_	0	0 3	3	3 3	_	0 0	1	5 4	2 6
New Mexico§	_	0	2	6	5	_	0	1	3	5	_	0	1	7	2
Utah Wyoming [§]	_	0 0	1 1	1 2	7 3	_	0 0	1 0	3	12	_	0 0	1 1	5 2	12 2
Pacific	2	5	10	253	90	5	3	10	159	169	1	5	19	240	226
Alaska California	2	0 3	2 10	5 196	10 71	5	0 2	2 8	6 119	2 120	1	0 3	2 19	5 169	1 164
Hawaii	Ň	0	0	N	N	_	0	1	3	2	—	0	1	5	10
Oregon [§] Washington	_	1 0	4 7	41 11	6 3	_	0 0	2 3	4 27	17 28	_	1 0	3 5	37 24	29 22
American Samoa C.N.M.I.	<u>N</u>	0	0	<u>N</u>	<u>N</u>	_	0	0	_	_	_	0	0	_	_
Guam Puerto Rico	N	0 0	0	N	N	_	0 0	2 1	3 1	1 3	_	0	0 1	3	8
U.S. Virgin Islands	N	0	0	N	N	_	0	0	_		_	0	0		

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 6, 2008, and December 8, 2007 (49th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands.

C.N.M.L. Commonwealth of Normer Martana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.
* Incidence data for reporting year 2008 are provisional.
* Data for meningococcal disease, invasive caused by serogroups A, C, Y, & W-135; serogroup B; other serogroup; and unknown serogroup are available in Table I.
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

(49th week)*	Pertussis						Ra	bies, anir	nal		F	Rockv Mo	untain sp	otted fever	
		Prev	ious					vious					ious		
	Current	52 w		Cum	Cum	Current		eeks	Cum	Cum	Current		eeks	Cum	Cum
Reporting area United States	136	169	Max 849	2008 8,561	2007 9,189	23	102	Max 160	2008 4,733	2007 5,739	12	42	Max 195	2008 2,196	2007 1,975
New England	5	13	49	591	9,169 1,455	23	7	20	4,733	5,739 504	12	42	195	2,190	1,975
Connecticut Maine [†]	_	0	4 5	34 40	86 78	_	4 1	17 5	190 55	210 84	N	0	0 0	N	N
Massachusetts	_	10	33	420	1,122	Ν	0	0	Ν	N	—	0	1	1	8
New Hampshire Rhode Island [†]	1 4	0 0	4 25	38 47	78 32	N	0 0	3 0	35 N	52 N	_	0 0	1 0	1	1
Vermont [†]	_	0	4	12	59	1	1	6	66	158	_	0	0		_
Mid. Atlantic New Jersey	18	19 1	43 9	950 54	1,219 214	12	28 0	63 0	1,516	961	1	1 0	5 2	78 12	81 31
New York (Upstate) New York City	8	7 1	24 5	406 46	510 146	12	9 0	20 2	480 19	499 43	_	0	2 2	17 24	6 27
Pennsylvania	10	9	22	444	349	_	18	48	1,017	419	1	ő	2	25	17
E.N. Central Illinois	33	24 5	189 18	1,473 293	1,453 189	_	3 1	28 21	244 103	408 113	_	1 0	13 10	128 84	59 39
Indiana Michigan	8	1 5	15 14	100 258	56 282	_	0 1	2 8	10 71	12 201	_	0	3 1	8	5
Ohio	25	9	176	715	601	_	1	7	60	82	_	0	4	32	10
Wisconsin W.N. Central		2 15	7 142	107 1,043	325 695	N 1	0 3	0 12	N 182	N 252	1	0 5	1 36	1 505	1 363
lowa Kansas		1	13	71 63	144 101		0 0	5	28	31 99		Ö 0	2	6	17 12
Minnesota	—	2	131	224	213	—	0	10	65	39	_	0	4	1	2
Missouri Nebraska†	17 12	6 2	49 34	414 238	102 69	1	0 0	9 0	53	38	1	4 0	35 4	475 20	313 14
North Dakota South Dakota	_	0 0	5 3	1 32	7 59	_	0 0	8 2	24 12	21 24	_	0 0	0 1	3	5
S. Atlantic	19	15	50	821	895	7	37	101	1,931	2,111	10	12	70	853	946
Delaware District of Columbia	_	0 0	3 1	16 7	11 9	_	0 0	0 0	_	_	_	0 0	4 2	31 8	16 3
Florida Georgia	10 2	5 1	20 6	282 67	205 35	_	0 6	77 42	137 298	128 286	1	0 1	3 8	18 73	16 60
Maryland [†]	3	2	8	117	113	_	8	17	403	416	_	1	7	68	63
North Carolina South Carolina [†]	3	0 2	38 22	79 108	292 78	4	9 0	16 0	434	465 46	9	2 1	55 9	450 53	610 62
Virginia† West Virginia	1	2 0	10 2	136 9	122 30	3	12 1	24 9	583 76	693 77	_	2 0	15 1	145 7	111 5
E.S. Central	6	7	18	327	453	_	3	7	165	149	_	3	23	306	273
Alabama [†] Kentucky	5	1 1	5 8	52 107	89 28	_	0 0	0 4	45	18	_	1 0	8 1	88 1	95 5
Mississippi Tennessee [†]	1	2 1	6 6	89 79	255 81	_	0 2	1 6	2 118	2 129	_	0 2	1 19	6 211	20 153
W.S. Central	5	27	198	1,451	1,051	_	1	40	85	1,023	_	2	153	282	205
Arkansas† Louisiana	5	1 1	18 7	81 70	159 21	_	0 0	6 0	47	31 6	_	0 0	14 1	65 5	109 4
Oklahoma Texas†	_	0 22	21 179	53 1,247	49 822	_	0 0	32 12	36 2	45 941	_	0 1	132 8	170 42	53 39
Mountain	6	15	37	729	1,047		1	8	76	97	_	0	4	38	36
Arizona Colorado	1 2	3 3	10 8	188 142	204 289	N	0 0	0 0	N	N	_	0 0	2 1	16 1	10 3
Idaho† Montana†	_	0 1	5 11	29 83	44 46	_	0 0	0 2	9	12 21	_	0 0	1	1 3	4
Nevada [†] New Mexico [†]	—	0	7	19 54	37 73	_	0	4 3	5 25	13 15	—	0	2	2 2	5
Utah	3	4	27	198	331	_	0	6	13	16	_	Ō	1	3	—
Wyoming [†] Pacific		0 24	2 303	16 1,176	23 921	2	0 3	3 13	24 188	20 234	_	0	2 1	10 4	13 3
Alaska California	8	3	21	233	86	2	Ō	4	14	43	Ν	0	0	Ň	N
Hawaii	1	8 0	129 2	383 16	430 18		3 0	12 0	160	179	N	Ō	1 0	1 N	1 N
Oregon [†] Washington	3	3 6	10 169	159 385	115 272	_	0 0	4 0	14	12	N	0 0	1 0	3 N	2 N
American Samoa		0	0	_	_	Ν	0	0	Ν	Ν	Ν	0	0	Ν	Ν
C.N.M.I. Guam	_	0	0	_	_	_	0	0		_	N	0	0	N	N
Puerto Rico U.S. Virgin Islands	_	0 0	0 0	_	_	N	1 0	5 0	59 N	47 N	N N	0	0 0	N N	N N
0.0. Virgin Islands		0	0			IN	U	0	11	IN	IN	0	0	11	IN

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 6, 2008, and December 8, 2007 (49th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting year 2008 are provisional. † Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

1341

(49th week)*	-																
	Salmonellosis						a toxin-p	roducing	E. coli (ST	EC)†	Shigellosis						
	Previou S2 weel							ious eeks					vious veeks				
Reporting area	Current week	Med	Max	Cum 2008	Cum 2007	Current week	Med	Max	Cum 2008	Cum 2007	Current week	Med	Max	Cum 2008	Cum 2007		
United States	583	826	2,110	42,003	44,389	44	86	250	4,838	4,565	409	427	1,227	18,791	17,555		
New England	1	19	487	1,646	2,191	2	3	47	216	306	_	2	39	155	240		
Connecticut Maine [§]	1	0 3	458 8	458 142	431 135	1	0	44 3	44 23	71 40	_	0 0	38 6	38 21	44 14		
Massachusetts	_	14	52	741	1,275	_	1	11	80	139	—	1	5	78	151		
New Hampshire Rhode Island [§]	_	3 1	10 8	138 92	165 105	1	0 0	3 3	34 8	35 7	_	0 0	1	3 10	5 23		
Vermont§	—	1	7	75	80	—	Ő	3	27	14	_	Ő	2	5	3		
Mid. Atlantic New Jersey	82	87 14	177 30	4,855 636	5,691 1,183	6	6 0	192 3	575 26	507 116	18	44 12	96 38	2,204 754	842 173		
New York (Upstate)	60	25	73	1,381	1,362	6	2	188	402	195	4	10	35	550	153		
New York City Pennsylvania	3 19	22 27	53 78	1,197 1,641	1,261 1,885	_	1 1	5 8	57 90	47 149	14	13 3	35 23	684 216	265 251		
E.N. Central	52	88	180	4,461	5,707	7	11	67	851	715	92	71	145	3,583	2,864		
Illinois Indiana	10	21 9	67 53	1,024 578	1,896 636	5	1 1	8 14	87 93	131 99	17	16 10	29 83	730 582	702 173		
Michigan	6	17	38	843	923	_	2	39	208	121	4	2	15	158	81		
Ohio Wisconsin	33 3	25 15	65 50	1,255 761	1,288 964	2	3 4	17 20	188 275	152 212	70 1	28 8	80 30	1,703 410	1,187 721		
W.N. Central	38	49	134	2,659	2,702	11	13	59	778	744	22	17	39	851	1,758		
lowa Kansas	1	7 7	15 31	389 449	456 399	_	2	20 7	193 51	173 51	2	3 1	11 5	157 62	101 25		
Minnesota	15	13	70	686	650	10	3	21	200	223	11	5	25	294	225		
Missouri Nebraska [§]	14 8	13 4	51 13	722 227	730 264	1	2 1	9 29	138 144	150 91	6 3	4 0	14 3	210 15	1,253 27		
North Dakota		0	35	45	45	_	0	29	3	9		0	15	37	5		
South Dakota	_	2	11	141	158		1	4	49	47		0	9	76	122		
S. Atlantic Delaware	241	247 2	457 9	11,499 143	11,716 138	11	13 0	50 2	751 12	654 15	43	58 0	149 1	2,900 9	4,348 11		
District of Columbia	123	1 100	4 174	49 4,956	59 4,694	1	0 2	1 18	12 142	140	13	0 15	3 75	14 776	18		
Florida Georgia	23	38	86	2,126	1,943	_	1	7	86	93	8	21	48	1,045	2,115 1,541		
Maryland [§] North Carolina	17 59	12 22	36 228	723 1,381	878 1,577	10	2 1	9 12	115 115	80 141	5 13	2 3	6 27	92 230	109 97		
South Carolina§	19	20	55	1,043	1,100		1	4	40	14	4	8	32	511	198		
Virginia [§] West Virginia	_	18 3	49 25	924 154	1,132 195	_	3 0	25 3	200 29	153 18	_	4 0	13 61	207 16	179 80		
E.S. Central	16	57	136	3,222	3,345	_	5	21	267	311	28	38	77	1,786	2,845		
Alabama [§] Kentucky	4 4	16 9	47 18	902 453	936 554	_	1 1	17 7	57 98	63 122	1	8 4	20 24	376 256	705 484		
Mississippi	5	13	57	1,025	1,023	_	0	2	6	7	_	5	45	288	1,332		
Tennessee§	3	15 107	56 894	842	832		2 6	7 27	106 299	119	27	17 90	43	866	324		
W.S. Central Arkansas [§]	48 4	107	894 40	5,458 739	4,985 802	1	6 1	3	299 41	253 43	154 15	90 11	748 27	4,527 551	2,221 84		
Louisiana Oklahoma		15 15	49 72	916 772	954 620	1	0	1 19	2 51	11 16	2	10 3	25 32	549 167	479 126		
Texas§	32	47	794	3,031	2,609	_	4	11	205	183	137	61	702	3,260	1,532		
Mountain Arizona	16 8	58 19	109 45	2,984 1,043	2,624 959	_	9 1	36 5	549 66	569 103	16 10	18 9	53 34	1,105 594	933 537		
Colorado	6	12	43	657	543	_	3	17	187	151	5	2	9	122	118		
Idaho [§] Montana [§]	_	3 2	14 10	177 115	147 104	_	2 0	15 3	141 31	128	_	0 0	2 1	14 8	13 25		
Nevada§	1	3	9	170	250	—	0	2	10	30	1	4	13	216	67		
New Mexico§ Utah	1	6 6	33 17	461 317	281 269	_	1	6 6	48 61	40 96	_	1	10 4	110 36	104 37		
Wyoming§	—	1	4	44	71	—	0	1	5	21	—	0	1	5	32		
Pacific Alaska	89 1	111 1	399 4	5,219 54	5,428 86	6	9 0	49 1	552 7	506 4	36	29 0	82 1	1,680 1	1,504 8		
California	82	78	286	3,815	4,101	5	5	39	294	266	35	26	74	1,450	1,213		
Hawaii Oregon§	_	5 6	15 20	244 399	297 316	_	0 1	5 8	13 64	31 76	_	1 2	3 10	40 90	70 75		
Washington	6	13	103	707	628	1	2	16	174	129	1	2	13	99	138		
American Samoa C.N.M.I.	_	0	1	2	=	_	0	0	_	_	_	0	1	1	5		
Guam	—	0	2	13	19	—	0	0	_	_	—	0	3	15	18		
Puerto Rico U.S. Virgin Islands	_	10 0	41 0	509	879	_	0 0	1 0	2	1	_	0 0	4 0	19	24		
S.O. Virgin Islands			0				U	0				0	0				

TABLE II. (*Continued*) Provisional cases of selected notifiable diseases, United States, weeks ending December 6, 2008, and December 8, 2007 (49th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Incidence data for reporting year 2008 are provisional. † Includes *E. coli* O157:H7; Shiga toxin-positive, serogroup non-O157; and Shiga toxin-positive, not serogrouped. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

(49th week)*		Strentococcal	diseases inv	asive, group A	Streptococc	Streptococcus pneumoniae, invasive disease, nondrug resistant [†] Age <5 years							
		Prev	ious	asive, group A			Prev	ious					
Reporting area	Current week	Med	eeks Max	Cum 2008	Cum 2007	Current week	52 w	еекs Max	Cum 2008	Cum 2007			
United States	60	95	259	4,805	4,861	34	34	166	1,528	1,740			
New England	4	6	31	320	365	_	1	14	71	120			
Connecticut Maine [§]	3	0 0	26 3	99 26	113 26	_	0	11	11 2	13 4			
Massachusetts	_	3	8	138	174	_	0	5	39	80			
New Hampshire Rhode Island [§]	1	0	2 9	27 18	27 8	_	0	1 2	11 7	13 8			
Vermont§	_	õ	2	12	17	_	ŏ	1	, 1	2			
Mid. Atlantic	15	18	43	945	885	1	4	19	201	305			
New Jersey New York (Upstate)	8	3 6	11 17	138 309	161 267	1	1 2	6 14	62 98	63 100			
New York City	_	3	10	178	218	_	0	8	41	142			
Pennsylvania	7	6	16	320	239	N	0	0	N	N			
E.N. Central Illinois	6	19 4	42 16	864 225	916 273	6	6 1	23 5	251 48	295 80			
Indiana	1	2	11	123	114	_	0	14	35	20			
Michigan Ohio	5	3 5	10 14	162 248	195 214	2 3	1	5 5	73 58	77 60			
Wisconsin		1	10	106	120	1	1	4	37	58			
W.N. Central	2	5	39	360	318	7	2	16	147	98			
lowa Kansas	_	0 0	0 5	 36	31	1	0	0 3	 19	2			
Minnesota	_	0	35	166	153	6	0	13	69	53			
Missouri	_	2	10	83	80	_	1	2	33	25			
Nebraska [§] North Dakota	1	1 0	3 5	40 12	24 18	_	0	2 2	8 8	17 1			
South Dakota	1	Ő	2	23	12	—	Ő	1	10	_			
S. Atlantic	10	21	37	1,042	1,191	8	6	16	284	316			
Delaware District of Columbia	_	0 0	2 4	9 24	10 17	_	0	0 1	2	3			
Florida	1	5	10	255	296	4	1	4	65	62			
Georgia Maryland§	3 3	4 4	14 8	229 170	241 203	1 3	1	5 5	66 57	77 64			
North Carolina	_	2	10	130	157	N	0	0	N N	N			
South Carolina§	3	1	5	70	97	—	1	4	48	55			
Virginia [§] West Virginia	_	2 0	12 3	123 32	144 26	_	0	6 1	38 8	48 7			
E.S. Central	1	4	9	165	200	_	2	11	94	97			
Alabama§	N	0	0	N	N	N	0	0	N	N			
Kentucky Mississippi	1 N	1 0	3 0	39 N	37 N	N	0 0	0 3	N 20	N 10			
Tennessee§	_	3	6	126	163	_	1	9	74	87			
W.S. Central	13	9	85	441	302	9	5	66	255	262			
Arkansas [§] Louisiana	_	0 0	2 2	5 16	17 16	_	0 0	2 2	7 10	16 35			
Oklahoma	2	2	19	110	65	1	1	7	60	57			
Texas [§]	11	6	65	310	204	8	3	58	178	154			
Mountain Arizona	6 1	10 3	22 9	505 184	547 202	3 2	4 2	12 8	208 106	234 115			
Colorado	4	3	8	141	137	1	1	4	56	46			
Idaho [§] Montana [§]	N	0 0	2 0	15 N	18 N	_	0 0	1	5 4	2 1			
Nevada [§]	<u> </u>	0	1	12	2	Ν	0	Ó	N	N			
New Mexico [§] Utah	1	2 1	8 5	93 54	101 82	_	0 0	3 3	17 19	40 30			
Wyoming§	_	0	2	6	5	_	Ő	1	1				
Pacific	3	3	8	163	137		0	2	17	13			
Alaska California	3	0 0	4 0	39	25	N N	0 0	0 0	N N	N N			
Hawaii	_	2	8	124	112		0	2	17	13			
Oregon [§]	N	0	0	N	N	N	0	0	N	N			
Washington	N	0	0	N 20	N	N	0	0	N	N			
American Samoa C.N.M.I.	_	0	12	30		N	0	0	<u>N</u>	N			
Guam		0	0		14		0	0					
Puerto Rico U.S. Virgin Islands	N	0 0	0 0	N	N	N N	0 0	0 0	N	N N			
0.3. Virgin Islanus		U	0			IN	U	0	N	IN			

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 6, 2008, and December 8, 2007 (49th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands.

C.N.M.L. Commonwealth of Normer Martana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.
* Incidence data for reporting year 2008 are provisional.
† Includes cases of invasive pneumococcal disease, in children aged <5 years, caused by *S. pneumoniae*, which is susceptible or for which susceptibility testing is not available (NNDSS event code 11717).
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

MMWR

(49th week)"		S	treptococ	cus pneui	noniae, ir	nvasive dise	ease, dru	g resistan	t†									
			All ages	-			A	ge <5 yea	rs		Syphilis, primary and secondary							
	Previous		50					ious					vious					
Reporting area	Current week	Med	Max	Cum 2008	Cum 2007	Current week	Med	eeks Max	Cum 2008	Cum 2007	Current week	Med	eeks Max	Cum 2008	Cum 2007			
United States	52	56	307	2,647	2,879	14	9	43	402	494	78	240	351	11,192	10,572			
New England		1	49	100	106	_	0	8	13	13	3	5	13	283	257			
Connecticut Maine [§]	_	0 0	48 2	55 16	55 12	_	0	7 1	5 2	4 2	1	0 0	6 2	31 10	33 9			
Massachusetts	_	0	0	—	2	_	0	0	_	2	2	4	11	203	150			
New Hampshire Rhode Island [§]	_	0 0	0 3	 16	20	_	0	0 1	4	3	_	0 0	2 5	19 13	28 34			
Vermont§	_	Ō	2	13	17	—	0	1	2	2	—	0	5	7	3			
Mid. Atlantic New Jersey	5	4 0	13 0	223	155	_2	0	2 0	22	29	12 4	32 4	51 10	1,586 195	1,457 216			
New York (Upstate)	1	1	6	59	51	1	Ō	2	7	10	4	3	13	130	130			
New York City Pennsylvania	1 3	1 2	5 9	67 97	104	1	0 0	0 2	15	19	4	21 5	37 12	1,012 249	858 253			
E.N. Central	5	13	64	642	738	_	1	14	88	119	8	20	34	951	835			
Illinois Indiana	_	0 2	17 39	71 187	193 157	_	0	3 11	14 21	45 24	2	5 2	14 10	246 129	432 51			
Michigan	_	0	3	16	3	—	0	1	2	2	1	3	19	204	109			
Ohio Wisconsin	5	8 0	17 0	368	385	_	1 0	4 0	51	48	4 1	6 1	15 4	319 53	184 59			
W.N. Central	3	2	115	146	236	_	0	9	10	44	5	8	15	368	344			
lowa Kansas	1	0 1	0 5	 59	 86	_	0 0	0 1	4	 10	3	0	2 5	15 29	20 28			
Minnesota	_	0	114	—	72	_	0	9	_	26	_	2	5	100	57			
Missouri Nebraska [§]	_2	1 0	8 0	80	61 2	_	0	1 0	3	3	_2	5 0	10 1	216 7	227 4			
North Dakota	_	0	0	_	_	—	0	0	_	_	—	0	1	_	1			
South Dakota S. Atlantic	 34	0 21	2 53	7 1,158	15 1,239		0 4	1 10	3 206	5 225	 26	0 52	1 215	1 2,534	7 2,415			
Delaware		0	1	3	<u>í</u> 11	—	0	0	—	2	_	0	4	[′] 15	´ 17			
District of Columbia Florida	27	0 13	3 30	18 691	20 673		0 3	1 6	1 138	1 121	1 7	2 20	8 37	125 946	169 843			
Georgia	6	7	23	353	465	_	1	5	56	93	<u> </u>	11	175	550	466			
Maryland [§] North Carolina	1 N	0 0	2 0	5 N	1 N	N	0 0	1 0	1 N	N	3	6 5	14 19	297 263	315 300			
South Carolina§	N	0 0	0 0	N	N	N	0 0	0 0	N	N	2 13	1 4	6 17	84 252	89 210			
Virginia§ West Virginia		1	9	88	69		0	2	10	8		4	1	252	210			
E.S. Central	4	5	15	256	258		1	4	43	36	6	21	37	1,051	861			
Alabama§ Kentucky	N 1	0 1	0 6	N 72	N 28	N	0 0	0 2	N 12	N 3	1	8 1	17 7	414 79	361 54			
Mississippi Tennessee§	3	0 3	2 13	4 180	56 174	_	0	1 3	1 30	33	5	3 9	19 19	161 397	108 338			
W.S. Central		2	7	82	86	_	0	2	12	33 11	6	9 41	61	1,975	1,786			
Arkansas§	_	0	2	16	6	_	Ō	1	3	2	5	2	19	163	115			
Louisiana Oklahoma	N	1 0	6 0	66 N	80 N	N	0 0	2 0	9 N	9 N	1	10 1	30 5	530 54	503 64			
Texas§	—	0	0	_	—	—	0	0	—	—	—	25	48	1,228	1,104			
Mountain Arizona	1	1 0	7 0	38	58	_	0 0	2 0	6	14	3	9 4	17 12	410 200	503 282			
Colorado		0	0				0	0			—	2	7	91	51			
Idaho [§] Montana [§]		0	0 1	N 1	N	N	0	0	N	N	_	0	2 3	6	1 5			
Nevada§	Ν	0	0	N	Ν	Ν	0	0	Ν	Ν	1	1	6	69	99			
New Mexico [§] Utah	1	0 0	1 7	2 32	41	_	0 0	0 2	6	11		1 0	4 2	40 1	44 17			
Wyoming§	—	0	1	3	17	—	0	1		3		0	1	3	4			
Pacific Alaska	N	0 0	1 0	2 N	3 N	N	0	1 0	2 N	3 N	9	44 0	65 1	2,034 1	2,114 7			
California	N	0 0	0 1	Ν	N	N	0	0	N 2	N 3	6	39	59	1,834	1,938			
Hawaii Oregon [§]	N	0	0	2 N	3 N	N	0	1 0	N N	3 N	_	0 0	2 3	19 24	8 17			
Washington	N	0	0	N	N	N	0	0	N	N	3	3	9	156	144			
American Samoa C.N.M.I.	N	0	0	N	N	N	0	0	N	N	_	0	0	_	4			
Guam	_	0	0	_	_	_	0	0	_	_	_	0	0	_	_			
Puerto Rico U.S. Virgin Islands	_	0 0	0 0	_	_	_	0 0	0 0	_	_	_	3 0	11 0	152	156			
		<u> </u>					~					~						

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 6, 2008, and December 8, 2007 (49th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. C.N.M.I: Commonwealth of Normern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Max * Incidence data for reporting year 2008 are provisional. † Includes cases of invasive pneumococcal disease caused by drug-resistant *S. pneumoniae* (DRSP) (NNDSS event code 11720). § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

<u> </u>						West Nile virus disease [†]										
		Varic	ella (chick	enpox)		Neuroinvasive Nonneuroinvasive§										
	Previous					Prev					Prev					
D	Current		veeks	Cum	Cum	Current	52 w		Cum	Cum	Current	52 w		Cum	Cum	
Reporting area	week	Med	Max	2008	2007	week	Med	Max	2008	2007	week	Med	Max	2008	2007	
United States New England	366 12	498 11	1,660 51	24,752 492	37,004 2.404	_	1 0	80 2	636 6	1,224	_	2 0	84 1	712 3	2,402 6	
Connecticut	12	0	28	492	2,404 1,362	_	0	2	5	5 2	_	0	1	3	2	
Maine [¶] Massachusetts	_	0 0	14 1	1	340	_	0 0	0 0	_	3	_	0 0	0 0	_	3	
New Hampshire	2	5	13	238	349	_	0	0	_		_	0	0	_	_	
Rhode Island [¶] Vermont [¶]	10	0 5	0 17	253	353	_	0	1 0	1	_	_	0	0	_	1	
Mid. Atlantic	45	47	80	2,131	4,504	_	0	8	46	22	_	0	5	19	11	
New Jersey New York (Upstate)	N N	0 0	0	N	N	_	0 0	1 5	3 23	1 3	_	0 0	1 2	4 7	1	
New York City	Ν	0	0	N	N	_	0	2	8	13	_	0	2	6	5	
Pennsylvania	45	47	80	2,131	4,504	—	0	2	12	5	—	0	1	2	5	
E.N. Central Illinois	118	135 14	336 63	6,337 1,054	10,589 1,079	_	0 0	8 4	44 11	112 62	_	0 0	5 2	22 8	65 38	
Indiana		0	222	0.607	222	—	0	1	2	14	_	0	1	1	10	
Michigan Ohio	38 78	58 47	154 128	2,637 2,215	3,965 4,321	_	0 0	4 3	11 17	16 13	_	0 0	2 2	6 3	1 10	
Wisconsin	2	4	40	431	1,002	—	0	1	3	7	—	0	1	4	6	
W.N. Central Iowa	26 N	21 0	145 0	1,170 N	1,522 N	_	0 0	6 3	46 5	249 12	_	0	23 1	173 5	739 18	
Kansas	9	6	40	437	550	—	0	2	8	14	—	0	4	30	26	
Minnesota Missouri	17	0 10	0 51	664	889	_	0	2 3	3 12	44 61	_	0	6 1	18 7	57 16	
Nebraska [¶]	Ν	0	0	N	Ν	—	0	1	5	21	—	0	8	44	142	
North Dakota South Dakota	_	0 0	140 5	49 20	83	_	0 0	2 5	2 11	49 48	_	0 0	12 6	41 28	320 160	
S. Atlantic	78	89	173	4,328	4,923	_	0	3	14	43	_	0	3	13	39	
Delaware District of Columbia	_	1 0	5 3	44 22	47 31	_	0 0	0	_	1	_	0	1 0	1	_	
Florida	37	29	87	1,553	1,209	_	0	2	2	3	_	0	0	_		
Georgia Maryland¶	N N	0 0	0 0	N N	N N	_	0 0	1 2	4 7	23 6	_	0 0	1 2	4 7	27 4	
North Carolina	N	0	0	N	N	—	0	0	—	4	—	0	0	—	4	
South Carolina [¶] Virginia [¶]	7 8	14 22	66 81	779 1,273	1,057 1,451	_	0 0	0 0	_	3 3	_	0 0	0 1	1	2 2	
West Virginia	26	12	66	657	1,128	—	0	1	1		—	0	0		_	
E.S. Central Alabama [¶]	9 9	18 18	101 101	1,073 1,060	665 663	_	0	9 3	56 11	74 17	_	0	12 3	84 10	99 7	
Kentucky	N	0	0	Ń	N	_	0	1	3	4	—	0	0	_	—	
Mississippi Tennessee [¶]	N	0 0	2 0	13 N	2 N	_	0 0	6 1	32 10	48 5	_	0	10 3	67 7	86 6	
W.S. Central	44	116	886	7,251	9,755	_	0	7	56	269	_	0	8	58	158	
Arkansas [¶] Louisiana	_	9 1	38 10	514 69	733 114	_	0	1 2	7 9	13 27	_	0	1 6	2 27	7 13	
Oklahoma	Ν	0	0	N	N	—	0	1	2	59	—	0	1	5	48	
Texas [¶] Mountain	44 33	107 36	852 90	6,668 1,838	8,908 2,572	_	0 0	6 12	38 99	170 289	_	0 0	4 23	24 184	90 1,040	
Arizona	—	0	0	´ —	· —	_	0	10	62	50	_	0	8	47	47	
Colorado Idaho¶	13 N	15 0	43 0	791 N	1,019 N	_	0	4 1	13 3	99 11	_	0	12 6	64 30	477 120	
Montana [¶]	12	5	27	312	401	_	0	0	_	37	_	0	2	5	165	
Nevada [¶] New Mexico [¶]	N 1	0 3	0 21	N 192	N 393	_	0 0	2 2	9 6	2 39	_	0 0	3 1	7 3	10 21	
Utah	7	9	55	533	725	_	0	2	6	28	_	0	5	20	42	
Wyoming [¶] Pacific	1	0 3	4 8	10	34 70	_	0 0	0 36		23	_	0 0	2 24	8 156	158	
Alaska	1	1	6	132 70	38	_	0	0	269	161	_	0	0	_	245	
California Hawaii	—	0 1	0 6	62		—	0 0	36 0	265	154	-	0	19 0	142	226	
Oregon [¶]	N	0	0	N	N	_	0	2	3	7	_	0	4	13	19	
Washington	N	0	0	N	N	—	0	1	1	—	—	0	1	1	—	
American Samoa C.N.M.I.	<u>N</u>			<u>N</u>	N	_	0	0	_	_	_		0	_	_	
Guam Puerto Rico	4	1 8	17 20	62 401	233 690	_	0 0	0 0	_	_	_	0 0	0 0	_	_	
U.S. Virgin Islands	4	0	20	401	- 690	_	0	0	_	_	_	0	0	_	_	

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending December 6, 2008, and December 8, 2007 (49th week)*

C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not notifiable. * Incidence data for reporting year 2008 are provisional. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

⁺ Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for California serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I.

⁸ Not notifiable in all states. Data from states where the condition is not notifiable are excluded from this table, except in 2007 for the domestic arboviral diseases and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm.
¹ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

TABLE III. Deaths in 122 U.S. cities,* week ending December 6, 2008 (49th week)

	All causes, by age (years)						, 2000 (4		All causes, by age (years)							
Reporting area	All Ages	<u>≥</u> 65	45–64	25–44	1–24	<1	P&I [†] Total	Reporting area	All Ages	≥65	45–64	25–44	1–24	<1	P&I [†] Total	
New England Boston, MA Bridgeport, CT Cambridge, MA Fall River, MA Hartford, CT Lowell, MA Lynn, MA New Bedford, MA New Bedford, MA New Bedford, MA New Haven, CT Providence, RI Somerville, MA Springfield, MA Waterbury, CT Worcester, MA Mid. Atlantic Albany, NY Allentown, PA Buffalo, NY Camden, NJ Elizabeth, NJ Elizabeth, NJ Erie, PA Jersey City, NJ New York City, NY Newark, NJ Paterson, NJ Philadelphia, PA Pittsburgh, PA [§] Reading, PA Rochester, NY Scranton, PA Syracuse, NY Trenton, NJ Utica, NY	602 149 36 17 35 66 22 22 13 33 U 78 1 47 2,587 52 32 32 32 32 32 21 18 83 21 18 67 29 1,149 32 21 580 40 26 167 13 40 67 13 149 32 18 18 18 18 18 19 19 19 19 19 19 19 19 19 19 19 19 19	$\begin{array}{c} 420\\ 90\\ 23\\ 15\\ 29\\ 40\\ 19\\ 12\\ 28\\ U\\ 59\\ -31\\ 16\\ 16\\ 58\\ 1,821\\ 40\\ 22\\ 57\\ 15\\ 15\\ 15\\ 15\\ 15\\ 374\\ 27\\ 27\\ 15\\ 13\\ 374\\ 27\\ 27\\ 131\\ 10\\ 355\\ 122\\ 20\\ 131\\ 10\\ 5122\\ 20\\ 111\\ 16\end{array}$	$\begin{array}{c} 132\\ 39\\ 12\\ 2\\ 5\\ 19\\ 3\\ 1\\ 5\\ 0\\ 12\\ 19\\ 3\\ 1\\ 5\\ 0\\ 12\\ 10\\ 9\\ 541\\ 11\\ 9\\ 12\\ 4\\ 2\\ 249\\ 111\\ 4\\ 2\\ 249\\ 111\\ 4\\ 144\\ 8\\ 4\\ 4\\ 27\\ 1\\ 3\\ 3\\ 3\\ 2\\ 2\\ 2\\ 2\\ 2\\ 2\\ 2\\ 2\\ 2\\ 2\\ 2\\ 2\\ 2\\$	27 12 	12 5 4 U 1 2 35 1 1 2 2 8 3 4 1 1 2 8 3 4 1 1 1 2	11 3 1 U 2 - 1 - 3 46 - 1 5 1 - 1 1 16 2 2 13	37 12 5 3 3 1 2 U 5 5 1 141 3 6 - 5 2 5 1 2 9 3 3 19 4 10 - 1	S. Atlantic Atlanta, GA Baltimore, MD Charlotte, NC Jacksonville, FL Miami, FL Norfolk, VA Richmond, VA Savannah, GA St. Petersburg, FL Tampa, FL Washington, DC. Wilmington, DC E.S. Central Birmingham, AL Chattanooga, TN Knoxville, TN Lexington, KY Memphis, TN Mobile, AL Montgomery, AL Nashville, TN W.S. Central Austin, TX Baton Rouge, LA Corpus Christi, TX Dallas, TX El Paso, TX Fort Worth, TX Houston, TX Little Rock, AR New Orleans, LA ¹¹ San Antonio, TX Shreveport, LA Tulsa, OK	$\begin{array}{c} 1,456\\ 108\\ 186\\ 153\\ 237\\ 143\\ 61\\ 78\\ 54\\ 55\\ 277\\ 92\\ 12\\ 941\\ 125\\ 102\\ 49\\ 111\\ 45\\ 125\\ 102\\ 49\\ 190\\ 1,749\\ 100\\ 1,749\\ 117\\ 47\\ 66\\ 240\\ 124\\ 168\\ 446\\ 104\\ U\\ 277\\ 48\\ 112\\ \end{array}$	917 58 103 108 144 102 41 49 37 36 179 55 5 5 619 148 69 74 27 80 80 74 29 118 69 74 29 118 1,136 172 37 56 142 37 59 112 274 U 112 274 U 112 274 U 112 277	$\begin{array}{c} 368\\ 26\\ 56\\ 29\\ 64\\ 32\\ 15\\ 16\\ 14\\ 14\\ 72\\ 27\\ 3\\ 222\\ 56\\ 14\\ 28\\ 12\\ 31\\ 18\\ 11\\ 52\\ 414\\ 28\\ 12\\ 31\\ 18\\ 11\\ 52\\ 413\\ 33\\ 7\\ 8\\ 8\\ 62\\ 29\\ 39\\ 117\\ U\\ 59\\ 526\\ \end{array}$	80 9 13 6 3 1 1 5 1 4 4 5 1 6 3 4 4 5 1 6 3 4 4 10 7 3 2 1 8 13 27 5 U 21 4 4	48 3 10 6 9 2 3 3 1 1 6 4 - 28 8 1 3 - 3 4 4 5 2 2 13 2 U 7 1 4	43 12 4 4 4 4 4 4 4 2 2 1 3 5 2 2 1 4 3 2 2 3 1 5 6 3 2 2 8 3 2 3 2 3 1 5 6 2 1 5 2 2 1 5 2 2 1 5 5 2 2 2 1 5 5 2 2 1 5 5 2 2 2 1 5 5 2 2 2 1 5 5 2 2 2 1 5 2 2 2 2	92 3 18 12 23 7 2 2 6 3 12 3 1 7 8 20 8 1 2 10 11 3 23 7 8 5 15 1 1 19 1 U 8 4 9	
E.N. Central Akron, OH Canton, OH Chicago, IL Cincinnati, OH Cleveland, OH Columbus, OH Dayton, OH Detroit, MI Evansville, IN Fort Wayne, IN Gary, IN Grand Rapids, MI Indianapolis, IN Lansing, MI Milwaukee, WI Peoria, IL Rockford, IL South Bend, IN Toledo, OH Youngstown, OH W.N. Central Des Moines, IA Duluth, MN Kansas City, KS Kansas City, KS Kansas City, MO Lincoln, NE Minneapolis, MN Omaha, NE St. Louis, MO St. Paul, MN Wichita, KS	$\begin{array}{c} 2,379\\ 6,66\\ 41\\ 133\\ 270\\ 212\\ 151\\ 187\\ 62\\ 69\\ 20\\ 72\\ 179\\ 52\\ 65\\ 64\\ 104\\ 67\\ 648\\ 44\\ 35\\ 32\\ 100\\ 53\\ 81\\ 86\\ 68\\ 55\\ 94\\ \end{array}$	$\begin{array}{c} 1,58\\ 42\\ 27\\ 254\\ 700\\ 194\\ 141\\ 111\\ 111\\ 85\\ 52\\ 47\\ 9\\ 9\\ 49\\ 120\\ 47\\ 63\\ 41\\ 49\\ 50\\ 81\\ 54\\ 446\\ 34\\ 446\\ 34\\ 26\\ 21\\ 67\\ 43\\ 53\\ 62\\ 31\\ 43\\ 66\end{array}$		135 4 2 39 9 13 9 7 18 2 4 2 3 1 3 5 2 1 31 4 6 5 5 7 1 3	45 9 4 2 5 1 8 1 2 2 4 1 1 1 1 2 2 4 1 2 4 1 2 4 1 1 2 2 1 2 4 1 2 1 2	47 - 10 4 1 8 5 3 3 5 2 - 1 3 2 1 1 3 2 1 1 3 2 1 1 3 2 1 1 3 2 1 1 3 2 1 1 3 2 1 1	1675533111691362	Mountain Albuquerque, NM Boise, ID Colorado Springs, CO Denver, CO Las Vegas, NV Ogden, UT Phoenix, AZ Pueblo, CO Salt Lake City, UT Tucson, AZ Pacific Berkeley, CA Fresno, CA Glendale, CA Honolulu, HI Long Beach, CA Los Angeles, CA Pasadena, CA Portland, OR Sacramento, CA San Diego, CA San Jose, CA San Jose, CA Sant Sacra, CA Sant Cruz, CA Seattle, WA Spokane, WA Tacoma, WA	875 U 35 85 76 217 40 82 42 135 163 1,787 17 115 33 64 67 257 29 84 212 228 130 195 34 135 89 98 13,024	597 U 288 59 47 154 27 41 32 92 27 117 1,247 13 72 28 46 50 175 24 59 136 162 92 138 25 88 66 73 8,789	188 U 55 17 21 43 100 255 8 29 300 375 3 3 23 4 12 13 55 9 41 1 27 43 8 33 15 59 41 127 43 8 33 17 18 2,945	50 U 1 6 5 10 1 7 1 9 10 85 - 8 - 4 2 14 - 5 112 7 7 1 8 3 3 7 12	19 U 1 4 2 5 1 2 3 47 7 1 1 7 1 1 7 3 8 2 6 4 2 3 299	21 U 2 3 6 4 3 3 3 1 5 1 1 1 5 2 2 3 5 2 1 2 1 1 2 1 1 2 78	49 U 2 1 6 17 3 3 9 7 172 9 8 7 9 32 5 24 16 16 16 4 10 7 4 8 840	

U: Unavailable. -: No reported cases.

U: Unavailable. —:No reported cases. * Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of >100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included. [†] Pneumonia and influenza. [§] Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks. [¶] Because of Hurricane Katrina, weekly reporting of deaths has been temporarily disrupted. ** Total includes unknown ages.

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, send an e-mail message to *listserv@listserv.cdc.gov*. The body content should read *SUBscribe mmwr-toc*. Electronic copy also is available from CDC's Internet server at *http://www.cdc.gov/mmwr* or from CDC's file transfer protocol server at *ftp://ftp.cdc.gov/pub/publications/mmwr*. Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Data are compiled in the National Center for Public Health Informatics, Division of Integrated Surveillance Systems and Services. Address all inquiries about the *MMWR* Series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop E-90, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333 or to *mmwrq@cdc.gov*.

All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.

☆ U.S. Government Printing Office: 2009-523-019/41144 Region IV ISSN: 0149-2195